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Background: An association between coffee consumption and the risk of cancer has long been 
investigated. This is particularly true for most commonly diagnosed cancer types such as, breast, 
endometrial, colorectal, lung, and ovarian cancer. Studies on the association between heavy coffee 
consumption and risk of less frequently diagnosed cancers are scarce. Coffee consumption among 
Scandinavian population is high, thus this is a favorable population in which to study the impact of 
coffee on cancer incidence.   
Objectives: We aimed to quantify the association between total coffee consumption and the risk of 
breast, colorectal, lung, ovarian, and cancer at any site. (Paper 1) Further objective was to assess the 
association between filtered, boiled, and total coffee consumption and the risk of bladder, esophageal, 
kidney, pancreatic, and stomach cancer. (Paper 2) Finally, we aimed to summarize the existing 
evidence on association between coffee consumption and the risk of endometrial cancer. (Paper 3) 
Methods: In paper 1, baseline information on total coffee consumption was collected from 91 767 
women in the Norwegian Women and Cancer Study. These information was updated from the follow-
up survey conducted 6-8 years after baseline. In paper 2, we used data from the Norwegian Women 
and Cancer Study and the Northern Sweden Health and Disease Study. Information on coffee 
consumption was available for 193 439 participants. Data on cancer incidence were obtained through 
linkage to the Norwegian Cancer Registry and the regional branch of the Swedish Cancer Registry. 
We used multivariable Cox proportional hazards models to calculate hazard ratios (HR) with 95% 
confidence intervals (CI) for the investigated cancer sites by category of total, filtered, and boiled 
coffee consumption. In paper 3, we searched online databases for studies published up to August 2016 
that aimed to investigate the association between coffee consumption and the risk of endometrial 
cancer. We estimated summary relative risks (RR) for cohort studies and odds ratios (OR) for case-
control studies with 95% CI by applying random effects meta-analyses. Dose-response analyses were 
conducted by using generalized least square trend estimation.  
Results: We found and a 9% reduced risk of cancer at any site (95% CI 3%-14%, ptrend=0.03) in 
women who drank more than 3 and up to 7 cups/day, compared to women who drank ≤1 cups/day. 
Consumption of more than 3 and up to 7 cups/day was associated with 17% reduced risk of colorectal 
cancer (95% CI 2%-30%) with no evidence of linear relationship (ptrend=0.10). A significantly 
increased risk of lung cancer observed with a coffee consumption of  >7 cups/day (HR=2.01, 95%CI 
1.47-2.75, ptrend<0.001) was most likely caused by residual confounding due to smoking, as no 
statistically significant association was observed in never smokers (>5 cups/day HR=1.42, 95%CI 
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0.44-4.57, ptrend=0.30). No significant association was found between coffee consumption and the risk 
of breast or ovarian cancer. 
Heavy filtered coffee consumption (≥4 cups/day) was associated with a reduced risk of pancreatic 
cancer (HR=0.74, 95% CI 0.57-0.95, ptrend=0.01). We did not observe significant associations between 
total and filtered coffee consumption and the risk of bladder, esophageal, kidney, and stomach cancer 
sites. We found some indications of a positive association between moderate boiled coffee 
consumption and the bladder cancer risk in women (HR=1.58, 95% CI 1.03-2.05), but this finding was 
not supported by the results from corresponding dose-response analysis (ptrend=0.56). However, we 
found an increased risk of bladder cancer among never smokers who were heavy filtered or total 
coffee consumers, and an increased risk of stomach cancer in never smokers who were heavy boiled 
coffee consumers. 
We identified twelve prospective cohort studies and eight case-control studies eligible for inclusion in 
the meta-analysis of coffee consumption and endometrial cancer risk. The summary RR for highest 
compared with lowest coffee intake was 0.73 (95% CI: 0.67–0.80, I2 = 36.7%) in the combined 
analysis of cohort and case-control studies. The corresponding RR among cohort studies was 0.76 
(95% CI: 0.69–0.83, I2 = 40.5%), and the meta-OR of 0.63 (95% CI: 0.53–0.76, I2 = 0%) was found 
after pooling the results from case-control studies. One-cup of coffee increment per day was 
associated with 3% (95% CI: 2% -4%) lower risk of endometrial cancer in cohort studies and 12% 
(95% CI: 5% -18%) in case-control studies. After pooling the results from five cohort studies, the 
association remained significant only in women with body mass index over 30. 
Conclusion: Increase in total coffee consumption was found to modestly reduce risk of cancer at any 
site, whereas increased filtered coffee consumption was associated with lower risk of pancreatic 
cancer. Our data suggest that increased coffee consumption does not affect the risk of breast, 
esophageal, colorectal, kidney, lung, and ovarian cancer sites. The positive associations between 
coffee consumption and the risk of bladder and stomach cancer were found in never smokers. The 
results from the meta-analysis indicate a protective effect of coffee consumption on the risk of 









Bakgrunn: En rekke studier har undersøkt sammenhengen mellom kaffeinntak og risiko for kreft, 
spesielt for de hyppigst forekommende kreftformene som bryst-, livmor-, tarm-, lunge- og 
eggstokkreft. Derimot fins det få studier av kaffeinntak og risiko for sjeldnere kreftformer. 
Kaffeinntaket i den skandinaviske befolkningen er høyt, og dette er et fortrinn når man ønsker å 
studere betydningen av kaffeinntak for kreftrisiko. 
Formål: Målet var å estimere sammenhengen mellom totalt kaffeinntak og risiko for kreft i bryst, 
tarm, lunge og eggstokk, samt total kreft. (Artikkel 1) Videre ønsket vi å studere betydningen av 
tilberedningsmetode (filterkaffe og kokekaffe i tillegg til totalt kaffeinntak) for kreft i blære, spiserør, 
nyre, bukspyttkjertel og mage. (Artikkel 2) Til slutt hadde vi som formål å oppsummere eksisterende 
studier av kaffeinntak og risiko for livmorkreft. (Artikkel 3) 
Metoder: I artikkel 1 ble informasjon om totalt kaffeinntak innhentet fra 91 767 kvinner i den norske 
studien Kvinner og kreft. Denne informasjonen ble oppdatert via et nytt spørreskjema 6-8 år senere. I 
artikkel 2 brukte vi data fra Kvinner og kreft og den nord-svenske helse- og sykdomsstudien NSHDS, 
hvor informasjon om kaffeinntak var tilgjengelig for 193 439 deltakere. Informasjon om kreftinsidens 
ble skaffet ved hjelp av koblinger til Kreftregisteret i Norge og det regionale kreftregisteret i Sverige. 
Vi brukte multivariable Cox’ regresjonsmodeller for proporsjonale hasarder for å beregne hasardratio 
(HR) med 95% konfidensintervall (KI) for de inkluderte kreftformene ved inntak av total-, filter- og 
kokekaffe. I artikkel 3 søkte vi i nettbaserte databaser etter studier publisert frem til august 2016, hvor 
formålet var å undersøke sammenhengen mellom kaffekonsum og risiko for livmorkreft. Vi estimerte 
samlet relativ risiko (RR) for kohortstudier og oddsratio (OR) for kasus-kontrollstudier med 95% KI 
ved å anvende randomiserte meta-analyser. Dose-responseffekter ble estimert ved en «generaliserte 
minste kvadrat» trendanalyse. 
Resultater: Vi fant en 9% redusert risiko for kreft totalt (95% KI 3% -14%, p-verdi for trend = 0,03) 
hos kvinner som drakk mer enn 3 og opptil 7 kopper per dag, sammenlignet med kvinner som drakk 1 
kopp eller mindre per dag. Inntak av mer enn 3 og opptil 7 kopper per dag var assosiert med 17% 
redusert risiko for tarmkreft (95% KI 2% -30%) uten noen lineær trend (p = 0,10). Vi observerte en 
signifikant økt risiko for lungekreft ved kaffeinntak på mer enn 7 kopper per dag (HR = 2,01, 95% KI 
1,47-2,75, p for trend <0,001), som mest sannsynlig var forårsaket av restkonfundering fra røyking, da 
ingen statistisk signifikant sammenheng ble observert hos aldri-røykere (> 5 kopper / dag HR = 1,42, 
95% KI 0,44-4,57, p for trend = 0,30). Ingen signifikant assosiasjon ble funnet mellom kaffeinntak og 
risiko for bryst- eller eggstokkreft. 
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Høyt inntak av filterkaffe (≥ 4 kopper / dag) var assosiert med redusert risiko for kreft i 
bukspyttkjertelen (HR = 0,74, 95% KI 0,57-0,95, p for trend = 0,01). Vi observerte ingen signifikante 
sammenhenger mellom inntak av total-, filter- eller kokekaffe og risikoen for kreft i blære, spiserør, 
nyre eller mage. Vi fant indikasjoner på en positiv sammenheng mellom moderat inntak av kokekaffe 
og blærekreft hos kvinner (HR=1.58, 95% KI 1.03-2.05), men dette funnet støttes ikke av resultatene 
fra dose-responsanalysen. (p for trend = 0.56). Imidlertid fant vi en økt risiko for blærekreft blant 
røykere med høyt inntak av filterkaffe eller kaffe totalt, og en økt risiko for magekreft hos aldri-
røykere med høyt inntak av kokekaffe. 
Vi identifiserte tolv prospektive kohortstudier og åtte kasus-kontrollstudier som var kvalifisert for 
inkludering i meta-analysen av kaffeinntak og risiko for livmorkreft. Samlet RR for høyeste 
sammenlignet med laveste kaffeinntak var 0,73 (95% KI: 0,67-0,80, I2 = 36,7%) i den kombinerte 
analysen av kohort- og kasus-kontrollstudier. Tilsvarende RR blant kohortstudier var 0,76 (95% KI: 
0,69-0,83, I2 = 40,5%), og meta-OR  0,63 (95% KI: 0,53-0,76, I2 = 0%) ble funnet etter å ha samlet 
resultatene fra kasus-kontrollstudier. En kopp økning i kaffeinntak per dag var assosiert med 3% (95% 
KI: 2% -4%) lavere risiko for livmorkreft i kohortstudier og 12% (95% KI: 5% -18%) i kasus-
kontrollstudier. Etter å ha samlet resultatene fra fem kohortstudier, forble sammenhengen signifikant 
bare hos kvinner med kroppsmasseindeks over 30. 
Konklusjoner: Vi fant en moderat reduksjon i risiko for kreft totalt ved høyt inntak av kaffe, mens 
økt inntak av filterkaffe var forbundet med lavere risiko for kreft i bukspyttkjertelen. Våre data tyder 
på at økt kaffeinntak ikke påvirker risikoen for kreft i bryst, spiserør, tarm, nyre, lunge eller 
eggstokker. En positiv assosiasjon mellom kaffeinntak og risiko for blære- og magekreft ble funnet 
bare hos røykere. Resultatene fra meta-analysen indikerer en beskyttende effekt av kaffeinntak på 
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1.1.1 Biological classification and history 
The genus of plants known as Coffea consists of over 70 species (1, 2). Most of the Coffea species can 
be found in the Equatorial region with the optimum altitude for growth being between 1300 meters 
and 1600 meters (3, 4). Our morning coffee is most likely made either of Coffea arabica or Coffea 
canephora (s. Coffea robusta), the two species dominating the coffee industry as they account for 
approximately 60% and 40% of the world coffee consumption, respectively. Other less grown species 
include Coffea liberica and Coffea excelsa, which contribute to up to 2% of world’s gross production 
and are considered to be of poorer overall quality (1, 2, 5).  
It is believed that coffee consumption originates either from Ethiopia or Yemen (6). The modern way 
of processing coffee beans by roasting and grounding was reported first in the Yemeni city Mocca in 
early 15th century (7). Even though the Ottoman Turks who had ruled Yemen tried to confine coffee 
use strictly within its borders, coffee consumption has spread via Istanbul to Venice in the beginning 
of the 17th century. Some decades later, coffee appeared first in France, and later in Vienna and 
England, reaching North America presumably in 1668 (6, 7).  
The first mention of coffee in Norway was recorded in 1694. During the early 18th century, coffee 
supressed alcoholic beverages as a “social lubricant” among the upper class of Norwegian society (8). 
By the late 18th century, approximately 250-300 gr of unroasted coffee per person was imported to 
Norway yearly through Copenhagen (8). The amount increased ten-fold by the mid-19th century when, 
Friele, a merchant from Bergen, started trading salted cod with coffee producers in Brazil, importing 
over 900 tonnes of coffee per year (9). At the time, coffee was made in copper kettles by boiling, with 
fish-skin and/or hot charcoal being commonly added into kettles before serving (10). Due to an 
increased coffee consumption among Norwegians throughout 1850s and 1860s, health authorities rose 
their concerns about its health effects for the first time (11). 
By the end of the 19th century, yearly coffee consumption in Norway had reached almost 4 kg per 
capita. This figure has fluctuated during the 20th century, rising up to 6.5 kg per person during the 
prohibition between 1916 and 1927, and plummeting to only 50 grams per week during the German 
occupation of Norway (12). After the World War 2, coffee consumption in Norway increased again, 
with 50% of coffee nowadays being imported from Brazil, and 25% from Colombia and Guatemala 
(12). Between 1997 and 2011, average consumption of coffee in Norway reached 9.4 kg/year per 
capita, and only Finland among Nordic countries was ahead with 11.7 kg (13). In the past few 
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decades, the preferred brewing method has changed among Norwegians. Filtered coffee is now 
considered by far the most popular brewing method surpassing both boiled and instant coffee as the 
alternatives (14). As from the late 1990’s and throughout 2000’s other types of coffee drinks such as 
macchiato, espresso, cappuccino, or café latte has become increasingly popular, while the 
consumption of decaffeinated coffee in Norway remains uncommon to this day (15). 
In Sweden, the average roasted coffee consumption between 2006 and 2016 was stable and 
averaged 7.95 kilograms per capita, which is a slight decrease compared to the period 
between 1997 and 2005 (8.2 kilogram per capita) (13, 16). The consumption peaked at 2010 
reaching 8.8 kilogram per person. However, the following year, the consumption of only 7.3 
kilogram of roasted coffee was reported per capita. The data from 2016 have shown the 
consumption of roasted coffee in Sweden amounted to 8.1 kilograms per capita. The total 
annual volume of roasted coffee consumed in Sweden averages 80 thousand metric tons (16). 
1.1.2 Coffee constituents 
Coffee as a beverage consists of numerous components which concentration and bioavailability 
depend on coffee type, roasting and brewing methods (17). 
Caffeine 
Caffeine is an alkaloid also known as 1,3,7-trimethylxanthine, with a chemical formula C8H10N4O2 
(Figure 1) (18). It is considered the most frequently consumed behaviorally active substance in the 
world (17-19), and other than in coffee, it can be found in tea, cocoa beverages, chocolate, energy 
drinks, and pre-workout beverages. On average, Coffea robusta contains more caffeine compared to 
Coffea arabica (19-21 mg/g vs. 10-12 mg/g, respectively) (20, 21). The content of caffeine seems to 
be dependent on brewing method, with boiled coffee having higher caffeine concentration per 100 ml 
compared to filtered coffee (22).  
 
Figure 1: Chemical structure of caffeine. Reprinted from: National Center for Biotechnology 
Information. PubChem Compound Database Copyright © 2018 with open access (23). 
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The peak plasma concentration of caffeine is reached 15-20 minutes after oral ingestion. It is absorbed 
completely by the stomach and small intestine, and it is able to pass all biological membranes (24, 25). 
The primary metabolism of caffeine in liver involves CYP1A2 (Cytochrome P450 1A2) enzyme that 
belongs to a cytochrome P450 oxidase enzyme system, and by N-acetyltransferase 2 enzyme (NAT2) 
(25-30). Caffeine has a half-life of approximately 5 hours in healthy adults and is mainly metabolized 
to paraxanthine (70-80%), and only a small fraction is excreted unchanged in the urine (25, 31).  
Caffeine exhibits the ability to improve physical (25, 32) and cognitive performance, such as vigilance 
and decreased reaction times (25). It is also shown to manage the symptoms of Parkinson’s disease 
(33, 34) and to have antioxidant properties (35, 36). Adverse effects of caffeine, such as increase of 
anxiety or jitteriness, are mainly the result of excessive amount of caffeine consumed and can also be 
a consequence of caffeine withdrawal (37, 38).  
 
Diterpenes 
Two diterpenes found in a coffee bean are cafestol and kahweol which were found to have 
anticarcinogenic properties (39, 40) (Figure 2). Studies have shown that kahweol could induce 
apoptosis in human leukemia cells (41), to reduce gentoxicity in hepatoma cells (42), and to induce 
synthesis of endogenous antioxidants (43), whereas both cafestol and kahweol were reported to induce 
apoptosis in human malignant pleural mesothelioma (44). On the other hand, coffee diterpenes were 
also found to increase serum cholesterol and might cause extracellular accumulation of low-density 
lipoproteins (45-48). Filtered coffee, as one of the methods of preparing coffee beverage, was found to 
have lower levels of diterpenes compared to boiled, espresso, or French press coffee (49-51), as the 
paper filter manages to block the passage of fine particles into the brew, and diterpenes being retained 
by the spent coffee (52, 53). 
 
Figure 2: Chemical structure of cafestol and kahweol. Reprinted from: National Center for 





Chlorogenic acids are polyphenolic compounds, with 5-caffeoylquinic acid being its major component 
found in coffee, and neochlorogenic, cryptochlorogenic, feruloylquinic, and dicaffeoylquinic acids also 
present in large quantities (18, 56-58) (Figure 3). It is one of the coffee ingredients with very high 
antioxidant activity (57, 59-63). In addition, it has been speculated that chlorogenic acids could 
decrease the risk of some cancers, and the proposed mechanism is that it reduces glucose levels in the 
blood and increases insulin sensitivity (64-67). Concentration of chlorogenic acids in a regular cup of 
coffee depends on type of coffee bean, roasting temperature, and brewing method (22, 57, 58, 68-70). 
Caffea robusta was found to have a higher content of chlorogenic acid compared to Caffea arabica, 
and therefore the higher antioxidant activity (22, 57, 61). Similarly, more pronounced antioxidant 
activity of boiled compared to filtered coffee could be the result of higher concentrations per cup of 
not only diterpenes but chlorogenic acids as well (22). 
 
Figure 3: Chemical structure of chlorogenic acid. Reprinted from: National Center for Biotechnology 
Information. PubChem Compound Database Copyright © 2018 with open access (71). 
Coffee Maillard Reaction Products  
During the process of high temperature roasting of green coffee beans, high molecular weight, 
polymeric chemicals named melanoidins are created as products of Maillard reaction (21, 72). The 
structures of these chemicals responsible for the taste and aroma of coffee beverage are difficult to 
determine, as melanoidins are modified to less known structures from polysaccharides, proteins, and 
phenolics (21, 73, 74). The products of Maillard reactions were also shown to have antioxidant 
properties (72, 75, 76), and the mechanism of antioxidant activity includes scavenging hydroxyl and 
proxy radicals, and breaking the radical chain (77). In vivo, these molecules were found to have a 
protective effect against oxidative stress in human hepatoma cells (78), to increase survival of human 
neuroblastoma cells from oxidative damage (75), and to suppress liver oxidative stress in rats (79). 
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1.1.3 Cancer incidence in Norway 
The incidence rate for all cancer sites combined has increased by 4.4% among Norwegian women in 
the five-year period from 2012 to 2016 compared to the period between 2007 and 2011. Breast, 
colorectal, and lung cancer remain the three most frequently diagnosed cancers in Norway and 
worldwide (80, 81). In Norway, age-standardized incident rate of breast cancer per 100 000 person-
years has increased by 7% from 2007–11 to 2012–16. Comparing the same periods, the incidence rate 
of lung cancer has increased by 9.4%. Women in Norway have one of the highest incidences of 
colorectal cancer in the Nordic countries, with 1588 new cases of colon and 517 new cases of rectal 
cancer diagnosed in 2016. The incidence of colon cancer has increased almost three-fold between 
1955 and 2014, while rectal cancer rates have stabilized after 1990s. On the other hand, a reduction in 
rates was recorded for ovarian (-7.4% between 2007–11 and 2012–16) and endometrial cancer (-
5.9%). In 2016, age-standardized (Norwegian standard) incident rate of esophageal cancer was 2.4 per 
100 000 women compared to 8.5 per 100 000 men. Similarly, higher rates are observed in Norwegian 
men compared to women for stomach (12.1 per 100 000 vs. 5.0 per 100 000), pancreatic (15.3 per 
100 000 vs. 11.5 per 100 000), kidney (22.9 per 100 000 vs. 10.1 per 100 000), and urinary tract (52.8 
per 100 000 vs. 16.9 per 100 000) cancer sites (80).  
1.1.4 Cancer incidence in Sweden 
From 2007 to 2016, the breast cancer incidence rates in Sweden have increased from 144 per 100 000 
to 163.4 per 100 000 women, and breast cancer remained the most frequently diagnosed cancer among 
Swedish women. In Swedish men, prostate cancer is the most commonly diagnosed cancer with about 
10,500 new cases being diagnosed in 2016. In the same year, the incidence rate of lung cancer was 
similar in men (35.5 per 100 000) and women (35.9 per 100 000) whereas higher rates of colon cancer 
were reported in men (47.1 per 100 000 vs. 42.1 per 100 000). Cancer of upper digestive tract was also 
more common in men (19.8 per 100 000) compared to women (9.6 per 100 000), which was also true 
for cancer of liver, pancreas and hepatobiliary tract (25.9 per 100 000 vs. 19.6 per 100 000), and 
cancer of kidney and urinary tract (62.2 per 100 000 vs. 23.5 per 100 000) (82).   
1.2 Coffee consumption and the risk of cancer – the story so 
far 
Because of the vast popularity of coffee beverages worldwide, any causal association between coffee 
consumption and chronic diseases would have a significant public health impact. The amount of 
evidence from epidemiological/health effect studies which had the aim to explore the association 
between coffee consumption and the risk of cancer, was mounting in the past two decades. In 2016, 
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the International Agency for Research on Cancer (IARC) published the Monograph in which they 
have evaluated the carcinogenicity of drinking coffee, maté, and very hot beverages, based on the 
available literature. In a summary of the final evaluations, the authors of the monograph stated that 
coffee drinking was not classifiable according to its carcinogenicity in humans (Group 3): “there was 
inadequate evidence of carcinogenicity in experimental animals and evidence suggesting lack of 
carcinogenicity in humans for cancers of the pancreas, female breast, and prostate, liver, and uterine 
endometrium, with inverse associations noted for the latter two sites” (83). 
Coffee consumption and bladder cancer 
The two epidemiological studies from Norway that aimed to explore the association between coffee 
drinking and the risk of bladder cancer included 16 555 and 43 000 Norwegian men and women, 
respectively (84, 85). The authors of both studies did not observe increase in the bladder cancer 
incidence among heavy coffee consumers. The recent meta-analysis of 25 case-control and five cohort 
studies revealed an overall meta-odds ratio (OR) of 1.33 (95% confidence interval (CI) 1.19-1.48) 
between coffee consumption and the bladder cancer risk (86). Finally, in the 2016 Monograph, the 
authors concluded there was no consistent evidence of an association between coffee consumption and 
bladder cancer risk, and that positive associations observed in some studies are most likely due to 
inadequate adjustment for smoking exposure, a known risk factor (83).  
Coffee consumption and breast cancer  
The two most recent meta-analyses on coffee consumption and the risk of breast cancer were 
published in 2013 and included 37 (87) and 26 (88) observational studies. Jiang et al. reported an 
inverse association for postmenopausal women and women that were BRCA1 mutation carriers (87), 
whereas Li et al. concluded that coffee drinking was not associated with the breast cancer risk (88). In 
Norway, Stensvold and Jacobsen found a statistically non-significant positive association between 
coffee consumption and the risk of most frequently diagnosed cancer in Norway (85). As mentioned 
above, the authors of IARC’s Monograph concluded that evidence from the available studies indicate 
lack of carcinogenicity for the female breast (83). The World Cancer Research Fund (WCRF) in their 
Continuous Update Project on how diet, nutrition, physical activity and body weight affect cancer risk 
and survival, concluded that the evidence on coffee and breast cancer risk are limited (89).   
Coffee consumption and colorectal cancer 
In the recent meta-analysis, Gun et al. found a 7% decreased risk of colon cancer for an increase in 
coffee intake by 4 cups per day (95% CI 1%-12%). In conclusion, the authors have stated that coffee 
consumption of at least 5 cups of coffee per day was inversely associated with the risk of colorectal 
cancer (90). Similarly, the findings from the Monograph suggest that that there are moderate evidence 
 
15 
of protective effect of coffee drinking on the risk of colorectal adenoma (83), whereas the authors of 
WCRF’s Continuous Update Project conclude that the evidence are limited/inconclusive (91). Among 
Norwegian women, the reported inverse association was not statistically significant for either colon or 
rectal cancer sites (85).   
Coffee consumption and endometrial cancer 
In two most recently published meta-analyses, coffee consumption was found to be inversely 
associated with the risk of endometrial cancer, and that the observed effect may be modified by body 
mass index (BMI), previous use of hormone replacement therapy (92), and menopausal status (93). 
The overall conclusion from these meta-analyses are in line with the conclusion from IARC’s 
Monograph (83), and from the Continuous Update Project (94).  
Coffee consumption and esophageal cancer 
There are little evidence indicating that coffee is associated with esophageal cancer (95, 96). However, 
there are strong evidence that consumption of hot beverages increases the risk of esophageal cancer 
(83, 96), based on the findings from one meta-analysis (95) and two studies from South America (97, 
98).   
Coffee consumption and lung cancer 
The results from a 2016 meta-analysis of 17 observational studies suggested that coffee consumption 
is associated with an increased risk of lung cancer (99), which was previously found in the study by 
Stensvold and Jacobsen (85). Galarraga et al. speculated that this association would be non-existent if 
effect of smoking is properly accounted for in the analyses, and indicated the importance of pooled 
analyses with large study groups of never smokers (100). In the WCRF’s Continuous Update Project 
report, the authors concluded that the evidence on coffee and lung cancer incidence are 
limited/inconclusive (101).  
Coffee consumption and ovarian cancer 
No association between coffee intake and incident ovarian cancer is was found in the study from the 
European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, and from a meta-analysis 
by the same authors (102). The same conclusion was made in the umbrella review of meta-analyses of 
coffee consumption and multiple health outcomes (103), and from the results of the Continuous 




Coffee consumption and pancreatic cancer 
A 2012 meta-analysis revealed no apparent association between high coffee intake and the risk of 
pancreatic cancer (105). However, in more recent meta-analysis of 20 cohort studies, Ran et al. 
concluded that high coffee consumption was in fact associated with the decreased pancreatic cancer 
risk (106). This finding was not supported by the IARC’s 2016 Monograph, nor by the authors of the 
Continuous Update Project (83, 107). Similarly, no significant relationship was found in two studies 
from Norway (84, 85). 
Coffee consumption and renal cancer 
In the Norwegian study from 1986, Jacobsen et al. found a strong inverse association between coffee 
intake and the renal cancer risk (84). This finding was later refuted by Stensvold and Jacobsen, who 
found no such relationship based on the data from 43 000 Norwegian men and women (85). This later 
finding was also backed up by the conclusion from the Continuous Update Project (108).  
Coffee consumption and stomach cancer 
Five meta-analyses published in 2015 and 2016 reported conflicting results regarding the relationship 
between coffee intake and the incident stomach cancer, ranging from decreased risk (109), no 
association for stomach cancer risk overall (110) and in the population outside of United States (111, 
112), to an increased risk (113). Limited evidence of an association was reported by the Continuous 














The overall aim of the thesis is to explore the association between coffee consumption and the risk of 
cancer.  
PAPER 1 
The aim was to investigate the relationship between heavy coffee consumption and the risk of breast, 
colorectal, ovarian, and lung cancers, as well as cancer at any site (overall cancer risk), in the 
Norwegian Women and Cancer (NOWAC) study. 
PAPER 2 
By pooling the data from two Nordic cohorts: the Norwegian Women and Cancer (NOWAC) Study 
and the Northern Sweden Health and Disease Study (NSHDS), we explored the association between 
filtered, boiled, and total coffee consumption and the risk of bladder, esophageal, kidney, pancreatic, 
and stomach cancer. 
PAPER 3 
We aimed to summarize the available evidence on the association between coffee intake and 















3 Material and methods 
 
3.1 Papers 1 and 2 
3.1.1 The Norwegian Women and Cancer Study 
The NOWAC study is population based cohort study that involves approximately 172 000 women 
from all over Norway. It was initiated in 1991 with the primary aim to investigate risk factors for 
breast cancer. The NOWAC Study has been described in detail by Lund et al (115). In short, random 
samples of Norwegian women aged 30-70 years was drawn from the Norwegian Central Population 
Registry and were invited to participate. The enrolment of women was conducted in three waves 
(1991, 1995-1997, and 2003-2007) (Figure 4). The food frequency questionnaire (FFQ) was added 
during the second wave of enrolment, whereas the collection of blood samples was initiated in 2003. 
More than 172 000 accepted and completed a questionnaire regarding their lifestyle, diet, and health 
status (overall response rate: 52.7%), and the NOWAC biobank consists of over 60 000 blood 
samples. All the participants received two follow-up questionnaires within 5 to 8 years between each 
follow-up. The NOWAC Study was approved by the Regional Committee for Medical Research 
Ethics and the Norwegian Data Inspectorate. All women gave written informed consent. 
3.1.2 Northern Sweden Health and Disease Study 
The NSHDS contains survey and biobank data from about 166 000 men and women in northernmost 
Sweden. It was initiated in 1985 and includes three population-based sub-cohorts: the Västerbotten 
Intervention Programme (VIP) cohort (participants aged 30, 40, 50 or 60 years), the MONICA 
(Monitoring Trends and Determinants in Cardiovascular Disease) cohort (participants aged 25-74 
years), and the mammography screening cohort (women aged 50-69 years). Dietary data administered 
by the Northern Sweden Diet Database (NSDD) are available in the VIP and MONICA cohorts. The 
participants of the ongoing VIP cohort that runs in the Northern Sweden’s Västerbotten county have 
undergone extensive health examination and have also answered questionnaires regarding diet, 
lifestyle and health conditions. The mean participation rate has been around 60% (116).  
The MONICA cohort includes inhabitants in the Västerbotten and Norrbotten counties randomly 
selected from the population registries that were updated every fourth to fifth year (117). The 
participation rate over the years of recruitment varied from 62% to 81%. The questionnaires used in 
the MONICA cohort are very similar to those used in the VIP cohort (116). The coffee study within 
the NSHDS was approved by the Regional Ethical Review Board of Northern Sweden, and all 







































3.1.3 Study population 
For paper 1, we used the information from the questionnaires of women enrolled in 1991-1992, 1996-
1997, 2003, and 2004. These women completed baseline food frequency questionnaires in 1998, 1996-
1997, 2003, and 2004, respectively. The information collected during the first wave (1991-1992) were 
not used in the study, as the version of questionnaires that was sent out did not include questions 
regarding diet. However, as the women enrolled during the first wave of data collection answered 
dietary questions in the follow-up survey in 1998, we used this information as baseline data for the 
present study. In total, 98 405 women answered the question regarding their coffee consumption.  
Women with prevalent cancer other than non-melanoma skin cancer at baseline and those who 
emigrated or died before the start of follow-up (N=4395), those who were diagnosed with cancer after 
they emigrated (N=9), and those with total energy intake above 15 000 kJ or below 2500 kJ per day 
(N=619), and those with missing information on coffee intake at baseline (N=1615) were excluded 
from the study. Our final analytical study sample consisted of 91 767 women. Follow-up information 
were available from 79 461 of these women, who received the follow-up questionnaire before the end 
of the study, 6-8 years after baseline data collection. The rest of the women (N=12 306) received the 
baseline questionnaire in 2004, while the follow-up questionnaire was sent out to them after the study 
had ended. 
In paper 2, the NOWAC cohort initially included 101 320 women, while the NSHDS cohort 
contributed 103 256 participants. As in paper 1, the data collected during 1991-1992 were not used in 
the study. After exclusion of those participants with prevalent cancer other than non-melanoma skin 
cancer at baseline, those who emigrated or died before the start of follow-up (N=8101), those that had 
missing information on coffee consumption (N=1615), and those with total energy intake above 15 
000 kJ or below 2500 kJ/day (N=1362), the final sample consisted of 145 247 women and 48 192 
men.  
3.1.4 Information on coffee consumption and covariates 
In the NOWAC cohort, the same question regarding coffee consumption was asked at baseline and at 
follow-up: “How many cups of each kind of coffee (boiled, filtered, instant) did you usually drink 
during the past year?” Women could choose from the following answers: never/seldom, 1-6 
cups/week, 1 cup/day, 2-3 cups/day, 4-5 cups/day, 6-7 cups/day, and ≥8 cups/day for each brewing 
method. For paper 1, we calculated total coffee consumption by summing the frequencies of each of 
the brewing methods, and categorized it as ≤1 cup/day (light consumers), more than 1 up to 3 cups/day 
(low moderate consumers), more than 3 up to 7 cups/day (high moderate consumers), and >7 cups/day 
(heavy consumers).  
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In the NSHDS cohort, the participants were asked the number of occasions on which they consumed 
filtered or boiled coffee with the following alternatives: never, a few times/year, 1-3 times/month, 1 
time/week, 2-3 times/week, 4-6 times/week, 1 time/day, 2-3 times/day, and >4 times/day.  
For the purpose of the paper 2, we assumed that 1 time/day from the NSHDS cohort matched 1 
cup/day from the NOWAC cohort. Total coffee consumption by summing the frequencies of filtered, 
boiled, and instant coffee in the NOWAC cohort and filtered and boiled coffee in the NSHDS cohort. 
Filtered, boiled, and total coffee consumption was then categorized as light consumption (≤1 cup/day), 
moderate consumption (>1-< 4 cups/day), and heavy consumption (≥4 cups/day). 
 
In paper 1, the following information were collected at both baseline and follow-up: BMI (body mass 
index), physical activity, alcohol consumption, total energy intake, and use of hormone replacement 
therapy (never, former, current), smoking status (never, former, current), and number of pack-years 
(calculated as number of cigarettes smoked/day divided by 20 and multiplied by years of smoking). 
We categorized as former smokers at follow-up those women who reported they were current or 
former smokers at baseline and non-smokers at follow-up (N=1608).  
In paper 2, we also utilized information on smoking status (never, former, current), alcohol 
consumption, BMI, total energy intake, and self-reported history of diabetes. 
 
3.1.5 Cancer incidence, death, and emigration 
We used the unique 11-digit personal number assigned to every legal resident in Norway, and the 
unique 12-digit personal number assigned to residents in Sweden to obtain information on cancer 
incidence, death, and emigration through linkage to the Norwegian Cancer Registry, the Cause of 
Death Registry, the Norwegian Central Population Register, the regional branch of the Swedish 
Cancer Registry, and Swedish National Cause-of-death Registry.  
The 7th Revision of the International Statistical Classification of Diseases, Injuries and Causes of 
Death was used to classify breast (170.0-170.9), colorectal (153.0-154.0), ovarian (175.0-175.9), and 
lung (162.0-162.1) (paper 1), and bladder (181.0-181.9), esophageal (150.0-150.9), kidney (180.0-
180.9), pancreatic (157.0-157.9), and stomach (151.0-151.9) cancer cases (paper 2) in the national and 
regional cancer registries.  
3.1.6 Statistical analysis 
In paper 1, we applied baseline information on coffee consumption and covariates until potential 
follow-up information, date of diagnosis of any incident cancer other than non-melanoma skin cancer, 
death, or emigration, whichever occurred first. Thereafter, we updated information on coffee 
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consumption and smoking variables until diagnosis of any incident cancer other than non-melanoma 
skin cancer, until death, emigration or the end of the study period (31 December 2013), whichever 
occurred first. In paper 2, person-years were calculated from start of follow-up until diagnosis of any 
incident cancer other than non-melanoma skin cancer, death, emigration, or the end of the study period 
(31 December 2014), whichever occurred first. 
 
Cox proportional hazards regression models were used to calculate hazard ratios (HRs) for developing 
breast, colorectal, ovarian, or lung cancer, as well as cancer at any site other than non-melanoma skin 
cancer in paper 1, and bladder, esophageal, kidney, pancreatic, or stomach cancer in paper 2, with 
95% CIs for each coffee consumption group. Light consumers (i.e., those drinking ≤1 cup/day), were 
used as the reference group, and attained age was used as the underlying time scale in both papers. In 
paper 1, all models were stratified by questionnaire subcohorts, (i.e. during which of the three waves 
of data collection a participant was included in the cohort), and by study cohort (NOWAC/NSHDS) in 
paper 2.  
In paper 1, analyses for each cancer site were adjusted for known risk factors for specific cancer type 
in the preliminary, complete-case analysis: menopausal status (premenopausal/postmenopausal), 
smoking status (never, former, current), age at smoking initiation (<20, ≥20 years), number of 
pack-years (≤14, 15-19, ≥20), exposure to cigarette smoke during childhood (yes/no),  
duration of education (≤9, 10-12,  13-16,  ≥17 years), body mass index (BMI, ≤18.49, 18.5-
24.9, 25-29.9, and ≥30 kg/m2), physical activity level (1-4, 5-6, 7-10), alcohol consumption 
(0, 0.1-3.99, 4-9.99, ≥10 g/day), number of children (0, 1-2, ≥3), age at first birth (<20, 20-24, 
25-29, ≥30 years), ever use of oral contraceptives (yes/no), duration of oral contraceptive use 
in years (continuous), use of hormone replacement therapy (never, former, current), maternal 
history of breast cancer (yes/no), total energy intake (tertiles, kJ/day), intake of fibers (<=20, 
>20 g/day), intake of processed meat (continuous, g/day), intake of red meat (<=10, 10.01-20, 
>20, g/day), height (continuous, cm), and participation in mammography screening (yes/no). 
For the analyses of colorectal, lung, and cancer at any site, smoking exposure was modelled as five-
categories variables, which included the information on smoking status, age at smoking initiation, and 
number of pack-years. We built the final models by assessing if the removal of the covariate lead to a 
change in the regression coefficients of at least 10% in any of the coffee consumption groups. In paper 
2, we adjusted for a variety of a priori selected risk factors: sex, smoking status (never, former, 
current), BMI (≤18.49, 18.5-24.9, 25-29.9, and ≥30 kg/m2), alcohol consumption (0, 0.1-3.99, 4-
9.99, ≥10 g/day), and self-reported history of diabetes (yes/no). In addition, the analyses of filtered 
coffee were adjusted for boiled coffee consumption and vice-versa. 
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The proportional hazards assumption was assessed by testing an interaction between coffee 
consumption and the logarithmic transformation of participants’ age in paper 1, and by assessing 
Schoenfeld residuals in paper 2. In both papers, we tested for linear trend across coffee consumption 
categories by assigning a median value to each category of the ordinal coffee consumption variable, 
which was then modeled as a continuous variable in the analysis. 
 
We checked if smoking status, BMI, and physical activity level modified the effect of total coffee 
consumption on studied outcomes in paper 1, and if BMI was effect modifier in the analyses of each 
brewing type in paper 2. In paper 1, by using information on women that were never smokers during 
the entire study period, we conducted the analyses of lung cancer to deal with residual confounding 
due to smoking. In paper 2, we conducted subgroup analyses according to smoking status (never/ever) 
for all of the outcomes. 
In paper 2, to assess a possible non-linear relationship between coffee consumption and the study 
outcomes, we modeled restricted cubic splines with four knots, with its locations based on Harrell’s 
recommended percentiles of the total and filtered coffee consumption (118), and positioned at the 25th, 
60th, and 95th percentiles of the boiled coffee distribution. We used a Wald-type test to assess if the 
coefficients of the second and third spline in filtered and total coffee analyses, and if the second 
spline’s coefficient in boiled coffee analyses were equal to zero. 
The use of repeated measurement in paper 1 on coffee consumption allowed us to conduct an 
extensive lag analysis in order to check for possible reverse causality. First, we have performed the 
analyses for every outcome after excluding cancers at the corresponding sites diagnosed during the 
first two years of follow-up. Second, we had excluded cancer cases diagnosed during the first year of 
follow-up while also censoring at the time of answering the second questionnaire those cancer cases 
diagnosed during the first year after they received the second questionnaire. In paper 2, a possible 
reverse causality was assessed by excluding cancer cases of interest diagnosed during the first year of 
follow-up.  
3.1.7 Multiple imputation 
In paper 1, assuming that data was missing at random, we performed multiple imputation by chained 
equations to deal with missing data. Twenty imputed datasets were created with ten iterations per 
dataset, in order to reduce sampling variability from the imputation simulation (119). The missing 
values were then replaced by imputed values based on the observed information. We created 
imputation models for each outcome, including all of the variables from the final analysis of the 
specific cancer sites, and the set of variables that we assumed could increase the predictive power of 
the imputation procedure, regardless of whether the variable(s) were used in the multivariable Cox 
regression model. Any significant interaction term between coffee intake and smoking status, BMI or 
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physical activity level in addition to the outcome indicator, and the Nelson-Aalen cumulative hazard 
estimator were included as predictors in all the imputation models (120). We used predictive mean 
matching using the 100 closest individual observations (nearest neighbors) from which imputed values 
were drawn as well as logistic regression, ordinal logistic regression, and multinominal logistic 
regression to impute continuous, binary, ordinal, and nominal variables, respectively.  
The estimates from the twenty imputed datasets were combined using Rubin’s rules in order to obtain 
HRs and corresponding 95% CIs (121, 122). 
In our study, the single population parameter of interest was a log HR from a Cox regression model, 
which will be denoted as Q. Then the multiple imputation point estimate of Q is the average of the m 
complete-data estimates (123): 
 
Further, we estimated a within-imputation variance component as the average of the complete-data 
variance estimates (123): 
 
Between-imputation variance is calculated by a combination of the complete-data point estimates 
(123): 
 





3.2 Paper 3 
3.2.1 Search strategy, study selection, and data extraction 
We performed a search of the electronic databases PubMed and Embase for studies published until 
August 2016 with the aim to quantify association between coffee intake and the risk of endometrial 
cancer. The following search strategy has been applied: ("coffee"[MeSH Terms] OR coffee[Text 
Word]) AND ("Endometrium"[Mesh] OR endometrial OR endometrium OR uterus OR corpus 
uteri) AND "Neoplasms"[Mesh] OR neoplasms OR cancer OR carcinogenic OR tumor) AND 
("Epidemiology"[Mesh] OR "Epidemiologic Studies"[Mesh] OR "Cohort studies"[Mesh] OR "Case-
control studies"[Mesh] OR case-referent OR case-control OR cohort). We included case-control, 
retrospective or prospective cohort studies that reported effect estimates with corresponding 95% CI 
for the association. We excluded the studies that did not adjust for body mass index and smoking as 
these are considered as key confounders.  
The data were independently extracted by two authors, and any disagreements were resolved by 
mutual discussion. The following information were extracted from each included study: first author’s 
last name, publication year, country of origin, study design, age of participants at study initiation, 
number of participants, person-years, and endometrial cancer cases, mean, median or duration of 
follow-up (cohort studies), number and type of cases and controls, mean age of cases and controls 
(case-control studies), covariates adjusted for in the analyses, information on principal strengths and 
limitations, risk ratios (RRs) from cohort studies and ORs from case–control studies with 95% CIs for 
each coffee consumption category.  
3.2.2 Statistical analysis 
ORs from case-control study and RRs from cohort studies were log transformed, after which standard 
errors of log-transformed effect estimates were calculated to compute summary RR or OR with 95% 
CI for the highest vs lowest (reference) category of coffee intake using random-effect models. The 
weight of each study was inversely proportional to the within-study sampling variances (124). We also 
conducted alternative analyses in which we first combined category specific estimates among coffee 
drinkers within each study into a single estimate for moderate to heavy coffee drinkers’ using a fixed 
effect model, after which we pooled single estimates using a random-effects model. 
We performed subgroup analyses according to BMI (<25, 25-30, >30), smoking status (never, former, 
current) use of hormonal replacement therapy (never, ever), caffeination status (caffeinated, 
decaffeinated), study location (Europe, North America), postmenopausal status for cohort studies, and 
the type of controls (hospital-based, population-based), postmenopausal status, and study location 
(Europe, Asia, North America), for case-control studies. 
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A dose-response analysis was conducted using generalized least squares for trend estimation method 
(125, 126). First, as the dosage values, we used medians reported in the studies or estimated them if 
the information was not available. Then, a variance-covariance matrix of the beta coefficients (log 
transformed RRs/ORs) in each of the studies was estimated to obtain dose-response relationship 
curves (125, 127). 
We modeled restricted cubic splines with three knots positioned at 2%, 25%, and 80% percentile of 
the coffee consumption distribution for cohort studies, and at 5%, 45%, and 80% percentile of the 
distribution for case-control studies. A non-linear relationship was assessed by testing the null 
hypothesis that the coefficients of the second spline were equal to zero (128). 




)  𝑥 100% 
where Q represents the value of chi squared statistics, i.e. the test that assesses if the observed 
differences in individual study results are compatible with chance alone, and df represents the tests 
degrees of freedom (129). The values ranging from 0-25% were considered as a low heterogeneity, 
from 26-50% as a moderate, and above 50% as a substantial heterogeneity between the studies (129).  
The difference in meta-estimates between study designs and between subgroups were tested by fitting 
meta-regression models (method of moments) and by conducting Wald’s tests.  
The risk of publication bias was tested by visual inspection of funnel plots presenting log-transformed 


















4.1 Paper 1 
During an average of 13.1 years of follow-up of 91 767 women, 9675 cases of cancer were diagnosed: 
3277 (33.9%) breast cancers, 1266 (13.1%) colorectal cancers, 446 (4.6%) ovarian cancers, and 819 
(8.5%) lung cancers. 
Compared to light coffee consumers (≤1 cups/day), women who drank more than 3 and up to 7 
cups/day had a 17% reduced risk of colorectal cancer (95% CI 0.70-0.98, ptrend across categories=0.10) and a 
9% reduced risk of cancer at any site (95% CI 0.86-0.97, ptrend across categories=0.03). A significantly 
increased risk of lung cancer was observed in women who were heavy coffee consumers (>7 
cups/day) compared to light coffee consumers (HR=2.01, 95% CI 1.47-2.75, ptrend across categories<0.001). 
However, no statistically significant association was observed in never smokers (>5 cups/day vs. ≤1 
cups/day HR=1.42, 95% CI 0.44-4.57, ptrend across categories=0.30). No significant association was found 
between coffee consumption and the risk of breast or ovarian cancer. 
The results from the complete-case analyses were similar to those from the analyses of multiple 
imputed datasets. We did not find evidence of violation of proportional hazards assumption. None of 
the interactions tested reached statistical significance. After we excluded breast cancer cases 
diagnosed during the first two years of follow-up, we found significantly decreased risk of breast 
cancer for low and high moderate coffee consumers compared to light consumers (HR=0.90, 95% CI 
0.81-0.99; HR=0.86, 95% CI 0.78-0.96, ptrend across categories=0.01). 
4.2 Paper 2 
The average follow-up of 145 247 women and 48 192 men was 13.6 years of follow-up. During more 
than 2.6 million person-years, a total of 19 733 cancer cases were identified, out of which 479 (2.4%) 
were bladder cancers, 97 (0.5%) esophageal cancers, 475 (2.5%) kidney cancers, 491 (2.5%) 
pancreatic cancers, and 281 (1.4%) stomach cancers.  
Compared to light filtered coffee consumers (≤1 cup/day), heavy filtered coffee consumers (≥4 
cups/day) had 26% reduced risk of being diagnosed with pancreatic cancer (95% CI 5%-43%, ptrend 
across categories=0.01). We did not observe significant associations between total or boiled coffee 
consumption and any of the investigated cancer sites, neither in the entire study sample nor in analyses 
stratified by sex. The reduced risk of pancreatic cancer was confined to never smokers (moderate vs. 
light filtered coffee consumers HR=0.60, 95% CI 0.41-0.87; heavy vs. light filtered coffee consumers 
HR=0.60, 95% CI 0.35-1.01; ptrend across categories=0.01).  
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Women who drank more than 1 and up to 4 cups of  boiled coffee per day had a HR of 1.58 (95% CI 
1.03-2.05) compared to light boiled coffee consumers. However, no association was found for women 
who drank more than 4 cups of boiled coffee, nor we found a statistically significant dose-response 
relationship. We found an increased risk of bladder cancer among never smokers who were heavy 
filtered coffee (HR=1.87, 95% CI 1.01-3.45, ptrend across categories=0.03) or heavy total coffee consumers 
(HR=1.86, 95% CI 1.12-3.10, ptrend across categories=0.08), and an increased risk of stomach cancer in never 
smokers who were heavy boiled coffee consumers (HR=2.14, 95% CI 1.10-4.16, ptrend across 
categories=0.04). 
No significant departure from linearity between filtered, boiled, and total intake and the study 
outcomes was found. The test of Schoenfeld residuals did not indicate a violation of the proportional 
hazards assumption. We found no evidence of effect modification between coffee consumption and 
BMI for any of the outcomes. The estimates for stomach cancer became stronger in the analyses 
performed after we excluded cases diagnosed during the first year of follow-up. 
4.3 Paper 3 
Twelve cohort (131-142) and eight case-control (143-150) studies were eligible for inclusion, 
contributing with 11 663 and 2 746 endometrial cancer cases, respectively. The summary RR for 
highest compared with lowest coffee intake category was 0.73 (95% CI: 0.67–0.80; pheterogeneity = 0.051, 
I2 = 36.7%) after combining results from the cohort and case control studies. The corresponding 
summary RR among cohort studies was 0.76 (95% CI: 0.69–0.83; pheterogeneity = 0.06, I
2 = 40.5%) and 
0.63 (95% CI: 0.53–0.76; pheterogeneity = 0.57, I
2 = 0%) for case-control studies. One-cup increment per 
day was associated with 3% risk reduction (95% CI: 2% -4%) in cohort studies and 12% (95% CI: 5% 
-18%) in case-control studies. We did not observe a statistically significant difference between the 
estimate from cohort and case-control studies (p=0.1), after applying a meta-regression model. We  
found evidence of an under-representation of smaller studies after a visual inspection of a funnel plot. 
After pooling the results from five cohort studies, the association remained significant only in women 
with body mass index over 30 (RR=0.71, 95% CI: 0.61-0.81). The summary RR for high vs low 
coffee consumption categories in postmenopausal women was 0.71 (95% CI: 0.62-0.81, pheterogeneity 
= 0.394, I2 = 4.2%). In cohort studies, a significant protective RR was observed for ever smokers (RR 
= 0.67, 95% CI: 0.49-0.92; pheterogeneity = 0.005, I
2 = 73.5%), never smokers (RR = 0.78, 95% CI: 0.67-
0.92; pheterogeneity = 0.302, I
2 = 17.2%) and former smokers (RR = 0.80, 95% CI: 0.66-0.97; pheterogeneity 
= 0.332, I2 = 0%). 
Inverse associations to risk of endometrial cancer were observed in sub-analyses of cohort studies for 
caffeinated (RR= 0.64, 95% CI: 0.49-0.83; pheterogeneity = 0.088, I
2 = 50.8%), decaffeinated coffee (RR= 
0.73, 95% CI: 0.59-0.90; pheterogeneity = 0.732, I
2 = 0%), and in never users of postmenopausal hormone 
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therapy (RR=0.59, 95% CI: 0.49-0.73; pheterogeneity = 0.579, I
2 = 0%). A negative association between 
high coffee intake and endometrial cancer risk was further observed across different geographical 
regions (Europe, Asia, North America). The association between coffee consumption and EC risk was 
attenuated when we conducted meta-analyses using the alternative approach in which we compared 























5.1 Summary of the results 
In paper 1, a decreased risk of cancer at any site was associated with high moderate coffee 
consumption. We found a statistically significant association between high coffee consumption (>7 
cups/day) and increased risk of lung cancer. However, residual confounding due to smoking may have 
contributed to the association between high coffee consumption and the risk of lung cancer. 
The data from the joint NOWAC and NSHDS cohort suggest that high filtered coffee consumption 
might reduce the risk of pancreatic cancer. No evidence of an association was found between coffee 
consumption and the risk of esophageal or kidney cancer. The positive association between bladder 
cancer risk and boiled coffee consumption in women who were moderate boiled coffee consumers was 
not supported by the findings from the dose-response analysis. Further, the increased risk of bladder 
and stomach cancer was found in never smokers.  
The results from the meta-analysis strengthen the evidence of a protective effect of coffee 
consumption on the risk of endometrial cancer and suggest that the effect of coffee intake is 
particularly beneficial for women with obesity. 
5.2  Discussion of methodology 
5.2.1 Methodological considerations in prospective cohort design 
5.2.1.1 Selection bias 
Selection bias occurs when a sample of study participants is not representative of the source 
population from which the sample was derived from, i.e. if there are systematic differences between 
those that participate in a study and those who do not (151). Several concerns can be raised in case of 
high percentage of non-responders. For example, if there are differences between responders 
compared to non-responders when it comes to demographics, life-style, health or diet.  
The response rate of 52.7% in the NOWAC cohort and the participation rate of 48-79% in the sub-
cohorts of the NSHDS study are similar to those in other population-based cohorts (152). The higher 
response in the NOWAC cohort was observed in the age-groups 30–34 years till 55–59 years (60%), 
while 44.7% responded among those aged 65–70 years (115, 152). The authors of a validation study of 
the cohort found no differences in oral contraceptive use, parity, and the level of education between 
the responders and the non-responders. Moreover, the study participants did not differ from the 
source population except for somewhat higher educational level (152).  
 
31 
Similarly, in the VIP cohort, only limited evidence of selection bias related to income, age, and 
unemployment was found. In both genders, the youngest group was less represented among 
participants. Participation was also lower in those that were unemployed compared to the employed, 
and in individuals that were in the lowest income level (153).  
The quality assessment of the MONICA project revealed that compared to participants, non-
participants were more often regular cigarette smokers, had somewhat lower BMI, and that a smaller 
proportion were married or cohabitant. No substantial differences were found in level of education 
(154, 155). Overall, the authors of the quality assessment conclude that the data from the MONICA 
cohort is of good quality (154, 156). 
Somewhat higher level of education observed in the NOWAC cohort, and the lower participation rates 
of those with a low income in the VIP cohort might have resulted in the measure of association 
between coffee intake and the risk of cancer that is, to an unknown degree, different from the source 
population due to a underrepresentation of heavy coffee consumers. Highly educated women in the 
NOWAC are less likely to be heavy smokers compared to lower educated women. As there is an 
observed positive correlation between smoking exposure and coffee intake, i.e. heavy smokers are 
more likely to be a heavy coffee consumers, this indicates that highly educated women drink less 
coffee compared to women with fewer attained years of education. Similar conclusion might be drawn 
in regards to the VIP cohort, as smoking and other forms of tobacco use are much higher among those 
with lower income, the group that was less likely to participate in the survey (157). Finally, as the non-
participants in the MONICA cohort were more likely to be active smokers, it might be speculated that 
heavy coffee consumers are slightly underrepresented in the NOWAC and the NSHDS cohorts.  
5.2.1.2 Information bias 
Information bias arises in an epidemiological study when systematic errors in measurements of 
exposure and/or outcome have occurred (158). Measurement errors of exposure can result in 
misclassification which can be divided in two groups. A non-differential misclassification is the result 
of measurement error of an exposure that occurred among participants independently of the study 
outcome. Contrary, a differential misclassification occurs when the extent of measurement error is 
different for those study participants with a disease and those without (151).  
As the data on coffee consumption and other covariates were collected from self-administered food-
frequency questionnaires (FFQ), a misclassification of a certain degree is possible. However, the FFQs 
used in the NOWAC cohort were validated by 24-hours dietary recalls study. The results from the 
validation study showed a high validity of information on coffee consumption (Spearman’s correlation 
coefficient r=0.82) (159). Moreover, a physical activity scale used to measure physical activity in 
NOWAC women, self-reported history of diabetes mellitus, as well as anthropometric measures, all 
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were shown to be reliable based on the results from the validation studies (160-162). Validation of 
food-frequency questionnaire measurements in the Northern Sweden Health and Disease cohort has 
shown that consumption frequencies of coffee were similarly measured by FFQ and 24-hours dietary 
recall regardless of preparation method (Pearson’s product moment correlations ranging between 0.72 
and 0.84) (163).  
In paper 1, we decided to use follow-up information on coffee consumption and on smoking exposure 
as the main confounder in order to take into account any intrapersonal variations that might have 
occurred during a follow-up of twenty years and thus reduce the risk of misclassification bias. 
In both NOWAC and NSHDS cohorts, we lacked information on certain types of coffee drinks such as 
espresso, cappuccino, café latte, macchiato, or decaffeinated coffee as these brewing methods were not 
asked about in the questionnaires. Even though a consumption of these coffee types was uncommon in 
Norway and Sweden at the time of data collection, it is still possible that total coffee consumption was 
underestimated for some of the participants, thus resulting in misclassification that is most likely to be 
non-differential. We also did not have information on instant coffee consumption from the NSHDS 
cohort. As instant coffee is prepared by freeze-drying filtered coffee, from a chemical point of view, 
this distinction is of less importance from a misclassification of brewing technique perspective. 
However, due to a lack of information on instant coffee intake, the total coffee consumption in 
Swedish cohort was somewhat underestimated.   
When self-reported, smoking exposure measures such as smoking status, number of cigarettes smoked 
per day, or duration of active smoking are particularly prone to measurement errors as smoking 
prevalence is often underestimated (164). Indeed, in the sample from paper 1, we observed 1 722 
women that reported being ever smokers at baseline and never smokers at follow-up, and the 
misclassification of this sort is unlikely to have occurred only in follow-up data. The observed risk 
estimates might have been stronger for the outcomes that were inversely associated with coffee 
consumption if the true distribution of smoking status was available from our data, whereas in case 
lung cancer risk, the observed positive association would have been weaker. We did not update 
information on other covariates other than coffee consumption and smoking exposure variables in 
paper 1. As the number of missing data in all covariates on follow-up was around 30%, we lacked 
computational power to perform multiple imputation on all the variables at both baseline and the 
follow-up. However, we conducted a complete-case analyses for all of the outcomes in which we had 
updated information on all of the covariates included in the analyses. The estimates from these 
analyses did not differ from the main results. For similar reasons, we could not use the repeated 
information from the third round of questionnaires in the NOWAC study in paper 1, nor have we 
updated information on the main exposure or covariates in paper 2. Due to proportion of missing in 
the NOWAC cohort for almost all of the covariates in the third measurement exceeding 50%, and the 
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analytical sample size in the paper 2 was close to 200 000 participants, we estimated that the multiple 
imputation for a single outcome would exceed 300 CPU (central processing unit) hours, and that the 
memory requirements would greatly exceed the capacities of a standard desktop computer. Therefore, 
due to a lack or incomplete update of the variables, some misclassification in papers 1 and 2 is 
probable, as it is unlikely that the study participants were drinking the same amount of coffee 
throughout the study period of 20 years. Moreover, the time-varying effect of covariates should be 
taken into account in an analysis, and the lack of proper adjustment in this regard could have led to 
biased estimates (165). Finally, further misclassification might have been introduced due to the 
different units of measurement of coffee consumption between the Norwegian and Swedish 
(occasions/day vs. cups/day), and due to individual variation in cup size.  
A misclassification in our studies, as in other cohorts, is more likely to be non-differential, as the data 
were collected before the outcome of interest has occurred. As a result, the observed effect estimates 
of an association between coffee consumption and the risk of studied outcomes might have been 
underestimated. 
A misclassification of outcome in the NOWAC cohort is less likely to have occurred and would have a 
small impact on the estimates, as the Cancer Registry of Norway is considered to be reasonably 
accurate and close-to-complete (98.8%) (166). Furthermore, the observed incidence rates for cancer 
sites in the NOWAC study were comparable to national figures (115, 152). At the same time, it is 
estimated that 99% of the cancer cases in the Swedish Cancer registries are morphologically verified 
and that the registry is generally considered to be of good quality (167). Further, cancer incidence 
rates in the VIP cohort do not differ from the figures in the population of Västerbotten at large (168). 
Therefore, the chance of misclassification of outcomes in papers 1 and 2 was minimal.  
5.2.1.3 Confounding  
A confounder is a factor that is associated with both study outcome and exposure of interest, and does 
not stand in the intermediate pathway of causation between the exposure and the outcome. Failing to 
adjust for a confounding effect in analyses can result in biased estimates in both directions and 
consequently erroneous conclusions (151). This might occur due to measurement error of a 
confounder, presence of undetected confounder, or suboptimal building of a regression model (169). 
Residual confounding occurs when the distortion of an estimate remains even after controlling for 
confounding by a measure of the confounding factor in the analysis.  
In all of our analyses, we a priori chose a set of potential confounders from the available literature. A 
potential confounder was included in the final model if its removal led to a change in the regression 
coefficients of at least 10% in any of the coffee consumption groups. This approach, however, can fail 
to identify a variable as a confounder if a measurement error of said variable has occurred (170). 
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Moreover, from a simulation study by Lee, cutoff points for the change-in-estimate criterion vary 
according to the effect size of the association between exposure and outcome, sample size, standard 
deviation of the regression error, and exposure–confounder correlation (171). Consequently, a 
possibility of residual confounding in paper 1 cannot be excluded. 
We lacked information on tea consumption in the NOWAC cohort since this information was not 
available from the questionnaires. As tea and coffee share many bioactive components, a confounding 
effect of tea consumption might be present which therefore might have confounded a true association 
between coffee consumption and the risk of cancer. Furthermore, in the NOWAC cohort, we did not 
have information on family history of cancer other than a breast cancer. If the family history of studied 
cancer outcomes was indeed related to coffee consumption, this could have introduced residual 
confounding in both paper 1 and 2.  
In paper 2, we lacked additional information on smoking exposure such as number of cigarettes 
smoked per day, number of pack-years, and/or duration of smoking in years in the Swedish cohort and 
information on family history of cancer was not available in neither of the two cohorts. However, as 
we did not observe any significant positive association between coffee consumption and the risk of 
five cancer sites, we believe that additional adjustment for aforementioned factors would not change 
our conclusions.  
The residual confounding by smoking might have particularly biased the estimates for the observed 
positive association between heavy coffee consumption and the risk of lung cancer. It is now well 
established that caffeine metabolism is accelerated in cigarette smokers and that the caffeine clearance 
is shorter among those who smoke (172-174). This implies that smokers need to consume more coffee 
in order to experience the same effect of caffeine as those who do not smoke. Indeed, we observed 
significant differences in coffee consumption between never, former, and current smokers in the 
cohort, with 68.5% of heavy coffee consumers being current smokers. We decided to use repeated 
measurements on smoking variables in order to adjust optimally for smoking exposure. However, we 
did not have information about such markers of smoking exposure as if a person inhales smoke from a 
cigarette, or lifetime exposure to secondhand smoke and other pollutants that would allow proper 
adjustment. In order to check if the positive association between heavy coffee consumption and the 
risk of lung cancer was indeed true, we performed a subgroup analysis on never smokers. Only after 
observing a non-significant association in this subgroup, we could suspect that residual confounding 
due to smoking may have contributed to the positive association in the analysis of the entire cohort.  
Additional residual confounding might be due to misclassification of the adjustment variables above 
discussed. If, for example, current smokers were classified as former smokers in the lung cancer 
analysis, this misclassification would strengthen the positive association between coffee consumption 
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and the lung cancer risk. Finally, modelling of continuous variables could have been a source of 
residual confounding in our analyses. If the association between a confounder and the outcome is not 
linear, the assumption of a linear relationship between the confounder and outcome specified in a 
model can result in inadequate control for confounding (175).    
5.2.1.4 Effect modification and reverse causality 
Effect modification occurs when two factors interact to change the risk of an outcome (151). For 
example, if smoking status modifies the effect of coffee intake on risk of lung cancer this would 
indicate that the association between coffee and lung cancer risk is different in never and ever 
smokers. Usually, in statistical analysis, effect modification is assessed by including a product of two 
variables (interaction term) that might interact in a regression model. 
We checked for possible interactions between coffee consumption and smoking status, BMI, and 
physical activity level in paper 1, and between coffee consumption and BMI in paper 2. The choice of 
these variables was based on their potential to either interact with the antioxidant effects of coffee, or 
affect the metabolism of coffee ingredients (176-178). Even though we did not observe any 
statistically significant effect modification, it should be noted that the interaction analysis are often 
underpowered as the number of cases within some of the subgroups could be insufficient in order to 
detect significant risk differences.  
Reverse causality is a phenomenon in which rather than an exposure influencing an outcome it is that 
the outcome is influencing the exposure or changes in the exposure. To illustrate, symptom of 
undiagnosed stomach cancer or precancerous lesions such as nausea, gastric reflux, vomiting can 
make a study participant change their hot beverage intake several years before the disease is actually 
diagnosed. Thus, the reported coffee consumption couple of years prior to diagnosis would not reflect 
a true long-term consumption. To take into account possible reverse causality, a usual approach is to 
conduct a sensitivity analysis in which cancer cases diagnosed during the first one or two years of 
follow-up are excluded. The estimates from this analysis are than compared to the estimates from the 
entire sample. 
In paper 1, the use of the updated information on coffee consumption made it possible to conduct 
extensive analyses in order to check for possible reverse causality. First, we performed sensitivity 
analyses after excluding cancer cases at the corresponding sites that were diagnosed during the first 
two year of follow-up. We then repeated the analyses after we had excluded cancer cases that occurred 
during the first year of follow-up, and at the same time censoring at the time of answering the second 
questionnaire those cancer cases diagnosed during the first year after they received the second 
questionnaire. No significant departures between the estimates from the reduced and complete samples 
were detected. In paper 2, we repeated the analyses after we excluded cancer cases of interest 
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diagnosed during the first year of follow-up. The exclusion of cases resulted in somewhat stronger 
association only between coffee consumption and stomach cancer risk, indicating that coffee habits 
have changed with the onset of the stomach cancer symptoms in at least some of the participants that 
were diagnosed with the disease.  
5.2.1.5 Multiple imputation  
Researchers usually address missing data by including in the analysis only complete cases —those 
individuals who have no missing data in any of the variables required for that analysis. However, 
results of such analyses can be biased. Furthermore, if the data are missing in several variables, the 
cumulative effect of missing data can lead to considerable reduction of the original sample, which in 
turn causes a substantial loss of precision and power (119). Conversely, single imputation methods, 
such as imputations with mean, median, or mode, although usually easy to perform, often lead to 
biased effect estimates and underestimation of standard errors, as these methods does not take into 
account uncertainty for the missing values (119, 179).  
There are three major types of missing: missing completely at random (MCAR), missing at random 
(MAR), and missing not at random (MNAR). Under the MCAR mechanism, there are no systematic 
differences between the missing values and the observed values i.e. the probability/reason of an 
observation being missing is independent of observed and unobserved infomation. Missing at random 
mechanism implies that systematic difference between the missing and the observed values can be 
explained by differences in observed data. Finally, if a missingness mechanism is missing not at 
random, then systematic differences remain between the missing values and the observed values, even 
after the observed data are taken into account (119). Unfortunately, it is not possible to distinguish 
between different missingness mechanisms without additional untestable assumptions (180). 
A complete-case analysis is valid if the missingness mechanism is MCAR, and can also be valid in 
certain situations under non-MCAR mechanisms. Specifically, if the reasons for the missing data in 
predictor variables are unrelated to the studied outcome, then analyses of complete cases will give 
unbiased results (119, 181). Multiple imputation will yield an unbiased estimates if the missingness 
mechanism is either MCAR or MAR, although there have been proposed methods for multiple 
imputation of MNAR data that would produce valid estimates and its standard errors (119, 182). 
Multiple imputation by chained equations (MICE) is a flexible and practical approach to generate 
imputations based on imputation models (183, 184). The MICE involves series of regression models 
from which missing data in a variable are replaced by simulated draws from the corresponding 
posterior predictive distribution of said variable. This means that each variable is modeled according 
to its distribution - binary variables modeled using logistic regression, ordinal variables modeled using 
ordinal logistic regression, and continuous variables modeled using linear regression or predictive 
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mean matching (183, 184). In other words, if we denote variable with missing value as x1, then the 
observed values on x1 are regressed (based on their posterior distribution) on the other variables 
specified in the imputation model, restricted to individuals with the observed x1. The missing values 
on x1 are then replaced by simulated draw from the posterior predictive distribution of x1, i.e. with the 
prediction from the regression model (183, 184). The subsequent step involves regressing the second 
variable with missing values, x2 on all other variables specified in the imputation model, using 
previously imputed values of x1, and restricted to individuals with the observed x2, and then replacing 
missing values from the posterior predictive distribution of x2. After these steps are repeated for all 
other variables with missing data, one cycle or iteration has been completed (184). To create one 
imputed dataset, 10 iterations are usually performed in order to stabilize the results (default in 
STATA) (184). It is usually recommended that no less than twenty datasets be imputed in order to 
reduce sampling variability from the imputation simulation (119). The estimates from the imputed 
datasets are then combined using Rubin’s rules to obtain point estimates and their standard errors as 
described in 3.1.7. 
As the proportion of missing data at follow-up was high (e.g. number of pack-years 42.8%), we 
performed MICE in order to deal with the missing data. We imputed missing information at baseline 
and follow-up under the assumption that data was missing at random, i.e. the probability/reason of an 
observation being missing is independent of unobserved infomation. We created twenty duplicate 
datasets for each outcome, with ten iterations per dataset for the burn-in period. Further, for each of 
the cancer outcome, we created separate imputation models that consisted of broad specter of 
variables, outcome indicator, interaction terms, and Nelson-Aalen cumulative hazard estimator in 
order to increase the predictive power of the imputation procedure (185). The possibility remains that 
at least some of the data was missing not at random, i.e. that their probability of being missing is 
dependent on unobserved information, which would make estimates calculated from the imputed 
datasets not free of bias. Furthermore, we did not have enough CPU power to impute more than 
twenty datasets for each of the outcomes, which would further reduce sampling variability and provide 
more stable estimates. 
As the estimates from the complete case analyses and the analyses from multiple imputed datasets 
were similar, it might be speculated that missingness mechanism was a case of missing at random in 
which missingness was driven by the explanatory variables, and given these, not the outcome (119) 
However, even if a missingness mechanism is assumed to be the special case of missing at random, a 
multiple imputation should be performed as a sensitivity analysis in order to check if the estimates 
between complete case analysis and the analysis of multiple imputed datasets are similar. 
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5.2.1.6 Non-linearity and restricted cubic splines 
A continuous variable as a predictor in a regression model assumes that there is a linear relationship 
between the predictor and an outcome. If this assumption is not true, then the regression model will be 
misspecified, i.e. the model will fail to show a true relationship between the predictor and the outcome 
(186). Categorizing a continuous variable is the most simple and frequently used method to investigate 
non-linearity. However, in this approach the effect of the predictor on the outcome is constant within 
each strata of categorized predictor. More so, by using cut-off points, it is not possible to estimate a 
smooth function between the predictor and the outcome from the model (186).  
Two flexible ways of addressing possible non-linear relationships are by applying restricted cubic 
splines or fractional polynomials models that allow flexible parametrization of a continuous variable 
(187). With restricted cubic splines, a continuous variable is still used in a model, but it is transformed 
in a way that produces linear relationship (186). The continuous predictor is divided into set of 
intervals, with the boundaries of the intervals being defined by the knots. Within each interval a cubic 
polynomial (polynomial of degree 3) function is fit. There are three continuity restrictions that are 
applied (187). First, if the assumption is that the function changes smoothly over time, then the 
estimated functions are forced to join at the knot locations. Second, the first derivate of the spline 
function, i.e. the gradient of the function, is also forced to agree at the knots. Final restriction is to 
force the second derivate, i.e. the rate of change in the gradient, to agree at the knots locations as well 
(187). Finally, the splines are restricted to be linear in the two tails, i.e. the function is forced to be 
linear before the first knot, and after the last knot locations (186). Cubic splines require k + 3 (where k 
is the number of knots) coefficients to be calculated in addition to the intercept, compared to 1 
coefficient in a linear model (186). 
The recommended number of knots is usually four to five (118, 188). Harrell suggests that three knots 
should be used if the sample size is small, three knots should be used so that enough observations 
between the knots are available to fit a polynomial function. If the sample size allows and if the 
relationship between a predictor and an outcome changes quickly, more than five knots can be used 
(118, 186). The location of the knots should ensure that there are sufficient number of observations 
between the knots to estimate the cubic polynomial (186).  
In papers 2 and 3, we modelled restricted cubic splines in order to assess a possible non-linear 
relationship between coffee consumption and the study outcomes. In paper 2, we modeled restricted 
cubic splines with four knots, with their locations based on Harrell’s recommended percentiles of the 
total and filtered coffee consumption. Harrell’s recommendation suggests placing knots at equally 
spaced percentiles of the original variable’s marginal distribution, and involves an additional 
restriction that the smallest knot may not be less than the fifth-smallest value of a predictor and the 
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largest knot may not be greater than the fifth-largest value of a predictor (118). The restricted cubic 
splines for boiled coffee were modeled with three knots, positioned at the 25th, 60th, and 95th 
percentiles of the coffee distribution. In paper 3, we modeled restricted cubic splines with three knots 
for both cohort and case-control studies, and the location of the knots was based on Harrell’s 
recommendations. In both papers, we used values of Akaike information criterion to ensure that the 
number and the location of the knots indeed best fit the data (189). In general, increasing number of 
knots from four to five in paper 2, and from three to four in paper 3, led to overfitting the data, 
whereas the changes of the knots’ location had less impact on the shape of the estimated function and 
the parameter estimates. 
5.2.1.7 External validity 
External validity is defined as “the degree to which results of a study may apply, be generalized, or be 
transported to populations or groups that did not participate in the study” (190). As discussed in 3.1.1, 
Norwegian women in the NOWAC cohort were randomly drawn from the population registry. Lund et 
al. concluded that the NOWAC cohort is externally valid as only negligible differences were found in 
level of education between study participants and the source population (115, 152, 191). Further, as 
mentioned previously, the incidence rates for all cancer sites in the NOWAC were almost identical to 
the figures from the Norwegian Cancer Registry (115, 152).  
The participants in the MONICA cohort were also randomly selected from the population registries. 
The participation rate of 60% in the VIP cohort and over 60% in the MONICA cohort along with no 
substantial differences in cancer incidence rates between the VIP and the figures in the population of 
Västerbotten (168) indicate that the external validity of NSHDS cohort is satisfactory.  
5.2.1.8 Other considerations 
In both papers 1 and 2 we used participants age as the underlying timescale. Some studies have shown 
that this approach is more appropriate for survival analysis compared to using time-on-study as time 
scale and then adjusting for participants’ age in a Cox model (192, 193).  
The proportional hazards (PH) assumption assumes that survival curves for different strata have 
hazard functions that are proportional over time. To our knowledge, in STATA before version 14, it 
was not possible to conduct the test of Schoenfeld’s residuals on m imputed datasets together, but 
rather on individual imputed datasets. Therefore, in paper 1, we checked the assumption by testing an 
interaction between coffee consumption and the logarithmic transformation of participants’ age. In 
paper 2, the PH assumption was checked by testing Schoenfeld’s residuals. In both papers, the 
assumption seemed not to be violated. However, statistical power to detect a violation of the PH 
assumption can be low to moderate even when the observed number of failures is high (194). 
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Finally, some of the analyses performed for certain outcomes performed were statistically 
underpowered which consequently could have led to failure to detect the effect of coffee consumption 
on the risk of some cancer sites when the effect was actually present. Specifically, in paper 1 the 
number of cases of lung cancer in the subgroup analysis according to smoking status was very low in 
never smokers. Similarly, in paper 2, the small number of cases hampered the analyses of esophageal 
cancer. Further, subgroup analyses by smoking status were underpowered in the analyses of bladder, 
esophageal and stomach cancer sites, an issue that was, again, more pronounced in never smokers. 
5.2.2 Methodological considerations in meta-analyses 
5.2.2.1 General considerations 
The limitations in the review are mainly related to the limitations of the individual studies included in 
the meta-analysis. In all of the studies, coffee consumption was self-reported through food-frequency 
questionnaires, with six studies overall not reported using validated FFQs. Therefore, the possibility of 
misclassification cannot be disregarded. Even though we restricted our meta-analysis to include only 
studies that adjusted for BMI and smoking status, and all but three cohort and one case-control study 
adjusted for some of the reproductive/menstrual factors, the presence of unknown confounders could 
have influenced the estimates. 
Additionally, some of the limitations were specific for case-control studies. Selection bias should be 
considered in interpreting the results from these studies. In order to minimize bias, controls from case-
control studies should be representative of the population from which the cases were derived (151). As 
three of the included case-control studies included hospital-based controls, which might not be 
representative of the underlying source population, selection bias cannot be excluded. In order to 
check if the pooled estimates were different between hospital-based and population-based case-control 
studies, we conducted subgroup analyses based on a selection of controls. We did not find a difference 
in the pooled estimates between population based and hospital based studies. 
Case-control-studies suffer to a different extent from recall bias. Recall bias arises “when participants 
in a study are systematically more or less likely to recall and relate information on exposure depending 
on their outcome status, or to recall information regarding their outcome dependent on their exposure” 
(195). As a consequence, misclassification of coffee consumption could  have occurred in the 
reviewed case-control studies. This would further warrant caution when communicating the results 
pooled from the studies with this design. However, even though the possibility of recall bias in case-
control studies cannot be excluded, it can be argued that the participants in these studies would not 
assume that coffee drinking might influence the risk of endometrial cancer, and therefore would be 
less likely to either underreport or over report their coffee drinking habits. 
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We decided to pool the results from both cohort and case control studies for several reasons. As 
endometrial cancer is a rare outcome, odds ratios from case-control studies will resemble risk ratios 
from cohort studies. Further, studies with a different design might be attempted when studies are 
addressing a common question (196). Nevertheless, we did provide separate results for the case-
control and cohort studies as well as pooled results, and a meta-regression model did not reveal 
significant differences between the estimates from cohort and case-control studies. 
5.2.2.2 Statistical heterogeneity 
Heterogeneity is defined as any kind of variability between the studies that are included in a meta-
analysis. The sources of variability might be due to a diversity of study participants or methodological 
diversity between the studies, such as different study designs, use of repeated measurements, 
difference in regression models, or use of different cut-off points when defining categories of a main 
exposure (197).  
We assessed the heterogeneity between included studies by calculating I2 statistics. The value of I2 
represents the percentage of variability in meta-effect estimates that is actually due to heterogeneity 
between studies and not sampling error. Interpretation of the I2 statistics should also take into account 
magnitude and direction of effect of studies, and strength of evidence for heterogeneity, i.e. p value 
from the chi-square test (129). There are several strategies to address heterogeneity when present. One 
of them is to perform a random effect meta-analysis. This type of analysis, unlike fixed-effect meta-
analysis, incorporates the assumption that the effects from the different studies are not identical but 
follow some distribution. As random effect model acknowledges the uncertainty on that the effect 
estimates between the studies are different (by treating the differences as random), the confidence 
interval around meta-effect estimates will be wider compared to a fixed-effect method, but only in the 
presence of heterogeneity (197). The other methods to tackle heterogeneity include exploring the 
heterogeneity by conducting sub-group analyses, changing the effect measure, excluding studies, or 
finally, not performing a meta-analysis altogether (197).  
To assess the level of heterogeneity based on the I2 statistics, we used cut-off points described in 3.2.2. 
All the meta-analyses were performed by the random effect method, and we conducted numerous 
subgroup analyses, to both further explore the effect of coffee consumption and the risk of endometrial 
cancer, and to investigate the observed moderate heterogeneity in the main meta-analysis. Even 
though the results from Paper 3 consistently indicate a protective effect of coffee intake on the risk of 
endometrial cancer, some caution should be exercised when interpreting the magnitude of this effect 
due to a moderate level of heterogeneity between the studies. Moreover, even though the I2 statistics is 
generally considered independent of the number of studies included in analysis, a recent study has 
 
42 
shown that the values of I2 statistics should be interpreted cautiously if a meta-analysis includes few 
studies, as the confidence interval around these values are often very wide (197, 198).  
In paper 3, we observed substantial heterogeneity (I2 > 50) in seven of the pooled analyses, in addition 
to six more analyses in which heterogeneity between the studies was moderate (I2 between 26 and 50). 
Interestingly, the meta-analyses that included both study designs had level of heterogeneity that was 
almost identical to the meta-analyses which included only cohort studies (32.0% vs 31.9%), contrary 
to the meta-analyses of case-control studies in which no heterogeneity between the studies was 
observed. However, the heterogeneity in subgroup analyses that involved both study designs was at 
least moderate in all but three analyses. In general, heterogeneity between case-control studies seemed 
lower than between studies with prospective cohort design. Heterogeneity was low in the analyses of 
studies from the same geographical region (United States, Europe, Asia) and was distinctively high in 
the subgroup analyses of current smokers, those with BMI over 25, as well as in the analyses of 
caffeinated coffee. As already suggested, differences in methodological choices that were made by the 
study authors, such as cut-off points that defined coffee-consumption categories, or adjustment factors 
that were included in analyses might have been the underlying reason for the observed levels of 
heterogeneity in our meta-analyses. Substantial heterogeneity that accompanied the analyses of 
overweight/obese women might be explained by the methodological approach that we used to 
combine the results. As described in 3.2.2, we combined category specific estimates among coffee 
drinkers within each study into a single estimate for moderate to heavy coffee drinkers’ using a fixed 
effect model, after which we pooled single estimates using a random-effects model. As some studies 
have reported coffee estimates for BMI categories 25-30 and above 30 separately, while other studies 
only reported the estimates for those with BMI above 25, this discrepancy could have been the reason 
of substantial heterogeneity between the studies, which was also found in the study by Lafranconi et 
al. (93). 
5.2.2.3 Publication bias 
Publication bias is a subtype of reporting bias which occurs when the dissemination of findings, 
mainly through publications, is influenced by the nature and direction of results (199). In their 
methodological review, Hopewell et al. found that randomized controlled trials with positive results 
had almost four times higher odds of being published compared to results that were not statistically 
significant (200). We performed a thorough search of the MEDLINE and EMBASE databases for 
relevant publications, and also checked references of previously published similar meta-analysis. A 
visual inspection of funnel plots, Egger’s, and Begg’s tests were used to assess the risk of publication 
bias. A funnel plot represents a scatter plot between log-transformed effect estimates (usually x axis) 
and standard errors of the estimates from the included studies (y axis). Any kind of asymmetry of a 
funnel plot could indicate a publication bias. Other than by visual inspection, asymmetry of a funnel 
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plot can be tested with Egger’s and Begg’s tests, which if significant at recommended 10% level could 
also raise an alarm regarding publication bias (199).  
If observed, however, asymmetry of a funnel plot does not necessarily need to be due to publication 
bias. Some reasons include poor methodological quality of smaller studies, a heterogeneity between 
studies, artefact, or chance alone. Statistical tests for checking a funnel plot asymmetry could also be 
misleading. The Egger’s test is usually not recommended for testing funnel plot asymmetry if the 
number of the included study is fewer than 10 or in the presence of a significant heterogeneity 
between the studies (199).  
Even though we did observe a substantial asymmetry of the funnel plot, indicating an under-
representation of smaller studies reporting positive associations between coffee consumption and the 
risk of endometrial cancer, it is likely that the asymmetry accurately reflects a lack of positive 
association, further suggesting lack of carcinogenicity for the association between coffee drinking and 
endometrial cancer (83). 
5.3 Discussion of the main results 
5.3.1 Paper 1 
5.3.1.1 Cancer at any site 
The results from paper 1 regarding the association between coffee consumption and the risk of cancer 
overall are in agreement with the results from the meta-analysis by Yu et al. (201). The authors found 
that women in the highest coffee consumption category had 13% lower risk of being diagnosed with 
any type of cancer compared to women in the lowest consumption category. In a prospective study 
from Norway, Stensvold and Jacobsen reported a statistically non-significant inverse association with 
cancer risk in women who consumed at least 7 cups/day, compared to women whose intake was no 
more than 2 cups/day (85).  
Although we did not observe statistically significant associations in all of the coffee consumption 
categories, indication of dose-response was observed based on a trend test suggesting that coffee 
consumption might reduce the risk of cancer overall. Even though the main analysis was adjusted for 
smoking status, number of pack-years and the age of smoking initiation, residual confounding could 
be the reason behind the lack of association in the highest coffee consumption category.  
As discussed in 1.1.2, a variety of biologically active substances contained in roasted coffee have the 
potential to either suppress or induce carcinogenesis. Chlorogenic acid is one of the ingredients that 
contributes significantly to the antioxidant effect of coffee. It has been hypothesized that chlorogenic 
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acid could alter the risk of some cancers by reducing glucose levels in the blood and increasing insulin 
sensitivity (62, 64). Polyphenolics from sweet potatoes, that consist of caffeic acid, chlorogenic acid, 
3,4-di-O-caffeoylquinic acid, 3,5-di-O-caffeoylquinic acid, 4,5-di-O-caffeoylquinic acid, and 3,4,5-tri-
O-caffeoylquinic acid, were found to suppress growth of human cancer cells (202). Chlorogenic acid 
was further found to have inhibitory effect on colon carcinogenesis in male rats (203). One of the 
proposed molecular mechanisms of antitumor effect of chlorogenic acid is that this coffee compound 
is inducting genes GSK-3β, APC, and inhibits gene β-catenin which promote tumor cell apoptosis in 
the Wnt pathway (204).  
Some of proposed anticarcinogenic mechanisms of kahweol include inducing apoptosis in human 
leukemia cells and synthesis of endogenous antioxidants (41, 43), and reducing genotoxicity in 
hepatoma cells (42). Further, kahweol was found to induce apoptosis of colorectal cancer cells in 
human by upregulating activating transcription factor 3 (205). Cafestol and kahweol were also 
reported to prevent genotoxic effect of N-nitrosodimethylamine and 2-amino-1-methyl-6-
phenylimidazol, carcinogens found in human diet, and to have protective effect against aflatoxin B1-
induced genotoxicity (42, 206). Finally, coffee diterpenes modify the effect of hepatic N‐
acetyltransferase and glutathione S‐transferase activity, which further contributes to chemoprevention 
against cancer (207).  
Caffeine could affect the risk of malignancies in pre- and postmenopausal women by increasing the 
level of sex-hormone binding globulin and decreasing the levels of free estradiol (208). It was also 
found to inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway (209). 
Studies have demonstrated that caffeine induces apoptosis in human neuroblastoma cells, in human 
A549 lung adenocarcinoma cells, and in mouse epidermal JB6 Cl 41 cells (210-212). 
5.3.1.2 Breast cancer 
The null findings regarding the association between coffee consumption and the risk of breast cancer 
found in paper 1 are in accordance with the meta-analyses by Jian et al., and Li et al., which included 
37 and 26 studies, respectively (87, 88). In a recent meta-analysis of 13 prospective cohort studies, 
Lafranconi et al. concluded that the coffee intake was not associated with the risk of breast cancer 
overall, but also reported that consumption of four cups of coffee per day was associated with a 10% 
reduction of breast cancer in postmenopausal women (213). Similarly, no apparent association was 
found in prospective studies from Norway, United Kingdom, France, Netherlands, United States, and 
Sweden (85, 139, 214-221). Our findings support the results from the EPIC cohort in which total 
coffee consumption was not associated with the risk of breast cancer in pre- or postmenopausal 
women (222). However, the authors of the EPIC study suggest that the high caffeinated coffee intake 
may reduce the risk of breast cancer in postmenopausal women. Further, the results from the Swedish 
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Women's Lifestyle and Health study showed a 19% (95% CI 6%-20%) decrease in risk of breast 
cancer in women who reported drinking at least 5 cups of coffee per day compared to women who 
drank 1-2 cups/day (223).  
We observed a borderline non-significant inverse association between high moderate coffee 
consumption (more than 3 up to 7 cups/day) and the risk of breast cancer, and a borderline non-
significant test of linear trend across consumption categories. The association became significant after 
we have excluded breast cancer cases that were diagnosed during the first two years of follow-up, as 
part of the lag-analysis.  
5.3.1.3 Colorectal cancer 
A meta-analysis of 19 prospective cohort studies have shown that coffee intake was not associated 
with the risk of colorectal cancer (highest vs lowest consumption category meta-RR=0.98; 95% CI 
0.90-1.06). The authors did find a significantly reduced risk of colon cancer for every 4 cups per day 
increase (meta-RR=0.93; 95% CI 0.88-0.99) (90). Akter et al. conducted a meta-analysis of 
observational studies conducted in Japan. They found a non-significant association in both genders 
after pooling the results from 5 cohort studies. Summary OR from seven case-control studies has 
shown that higher coffee intake was reducing the risk of colorectal cancer by 22% (95% CI 5%-35%, 
I2=51.6%) (224). 
Authors from the EPIC cohort concluded that coffee consumption was not likely to be associated with 
the risk of colorectal cancer (225), as did the authors that used the data from the National Cancer 
Institute - Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (226), the authors from the 
Singapore Chinese Health Study (227), the authors from the Miyagi Cohort Study (228), and the 
authors that used the data from the Women's Health Initiative Observational Study (229). Moreover, 
no association between coffee consumption of at least 10 cups of coffee per day and the risk of 
colorectal cancer was reported in the cohort of Finnish women (230). Studies from Sweden and the 
United States that used a similar method of updating information on coffee consumption, also found 
no association between high coffee consumption and the risk of colorectal cancer in women (231, 
232). In a recent pooled analysis of 8 cohort studies from Japan, the authors found that coffee 
consumption was not associated with the risk of colorectal cancer in women, but reported a 20% (95% 
CI: 1%-36%) reduced risk of colon cancer in female women who reported drinking at least three cups 
of coffee per day (233). A meta-analyses of 19 prospective cohort studies found the coffee intake was 
significantly reducing the risk of colorectal cancer at ≥ 5 cups per day of coffee consumption in men 
and women combined (90). The results from the NIH-AARP Diet and Health Study have shown that 
compared to not drinking, consumption of at least 6 cups of caffeinated coffee per day was reducing 
the risk of colon cancer in women by 31% (95% CI 8%-55%) (234).  
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Even though we found an association between high moderate coffee consumption and colorectal 
cancer risk, an absence of significant associations in remaining coffee consumption categories, and no 
evidence of linear relationship across consumption categories support the findings from the 
abovementioned studies. Furthermore, coffee consumption was associated with neither colon nor 
rectal cancer in the separate analyses. 
5.3.1.4 Ovarian cancer 
The results from paper 1 regarding ovarian cancer are in line with those from the EPIC cohort. The 
same authors conducted a meta-analysis of 5 cohort studies and confirmed lack of evidence to support 
an association between coffee and tea consumption and risk of ovarian cancer (102). No significant 
association was also reported in the studies from Netherlands and Sweden (235, 236) and in a recent 
Mendelian randomization study (237). Silvera et al. used the data from the Canadian National Breast 
Screening Study to find a HR of 1.62 (95% CI 0.95-2.75) of developing ovarian cancer for the women 
who reported drinking more than 4 cups of coffee per day compared to coffee abstainers (238).  
Our findings strengthen the evidence of no association between coffee consumption and the risk of 
ovarian cancer. 
5.3.1.5 Lung cancer 
In 2010, Tang et al. reported a positive association between coffee consumption and the risk of lung 
cancer in the meta-analysis that included 5 cohort and 8 case-control studies (highest vs. lowest 
quantile meta-RR=1.27; 95% CI 1.04 - 1.54, increase of two cups per day meta-RR=1.14; 95% CI 
1.04–1.26) (99). Later, Wang et al. complemented the analyses and concluded that there is a linear 
dose-response relationship between coffee consumption and risk of lung cancer (239). In two recent 
meta-analyses of epidemiological studies, Xie et al. found a non-significant summary OR of 1.16 for 
women in the highest coffee consumption category (99), whereas Galarraga et al. concluded that the 
association between coffee consumption and lung cancer might be confounded by tobacco smoking, as 
they found no association in never smokers (100). Stensvold and Jacobsen reported a two-fold 
increased risk of lung cancer in Norwegian women that were consuming at least 7 cups of coffee per 
day compared to those who drank no more than 2 cups (85). In the study from United States, a non-
significant higher risk of lung cancer in women was associated with the highest level of coffee intake 
(≥4 cups/day vs ≤1 cup/day HR=1.10; 95% CI 0.95-1.26). The authors of the study concluded that the 
observed positive association found in both genders combined is most likely due to an imperfect 
adjustment for smoking exposure (240). Finally, coffee consumption was associated with the 




A strong correlation between smoking habits and coffee consumption observed in paper 1 can be at 
least partially explained by the shared metabolic pathway between caffeine and nicotine, via the 
CYP1A2 gene (27, 242), which is the main caffeine-metabolizing enzyme (243). Sulem et al. 
conducted a meta-analysis of genome-wide association studies of coffee consumption and found 
sequence variants related to coffee consumption habits that were located between CYP1A1 and 
CYP1A2 and near the aryl hydrocarbon receptor, which regulates the expression of the CYP enzymes 
(243). As both caffeine and nicotine upregulate the CYP1A2 pathway (242, 244), active smokers 
would need more caffeine compared to non-smokers in order to feel the effect of it (240). Indeed, a 
recent Mendelian randomization study confirmed that heavier smoking causally increases coffee 
intake (174). Therefore, any imperfect adjustment for smoking exposure could result in positive 
associations between coffee consumption and lung cancer risk. 
Residual confounding due to smoking is a probable reason of the observed association between coffee 
consumption and the risk of lung cancer in paper 1. In order to counter the effect of residual 
confounding, we performed the analysis in never smokers, and found no evidence of an association. 
However, a small number of lung cancer cases among never smokers limited our analysis, and wide 
confidence intervals indicated that the results, even though they were not statistically significant, were 
imprecise. Therefore, even though the results were not significant at 5% level, and that we did not 
observe a significant trend between coffee consumption and the risk of lung cancer among women that 
had never smoked, some caution is necessary when interpreting the results from this analysis.  
Some biological effect of coffee compounds could also provide a background to the observed positive 
association between coffee consumption and lung cancer. In contrast to its anticarcinogenic properties, 
caffeine was also reported to inhibit DNA repair mechanisms (245, 246). A study by Muller et al. have 
shown that caffeine negatively effects both the speed of DNA repair, and the residual damage after 
exposing mammalian cells to radiation (247).  
Recently, the role of dietary acrylamide in carcinogenesis has been investigated. IARC has classified 
acrylamide in group 2A of carcinogens, i.e. as probable carcinogen to humans. Acrylamide is a 
chemical used in many industrial processes, but is also found in food and cigarette smoke (248, 249). 
Coffee is one of the major sources of dietary acrylamide (250). A survey from United States has 
shown that its levels ranged from 45 to 374 ng/g in unbrewed coffee grounds, from 172 to 539 ng/g in 
instant coffee crystals, and from 6 to 16 ng/mL in brewed coffee (251). The authors of a study from 
Sweden reported that coffee contributes with about 39% of total dietary acrylamide intake in Swedish 
population (252). In a study by Mojska et al., the levels of acrylamide was found to be highest in 
coffee substitutes (818 microg/kg), followed by instant coffee (358 microg/kg), and roasted coffee 
(179 microg/kg). The authors, however, did not find significant differences in the acrylamide levels 
between Coffea arabica and Coffea robusta (253). The studies have shown that acrylamide can induce 
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DNA adduction and mutagenesis, tumorigenesis, and was also shown to have a genotoxic potential 
(254). However, in two recent comprehensive literature reviews of epidemiologic studies of dietary 
acrylamide intake and the risk of cancer, the authors concluded that there are no consistent evidence 
that dietary acrylamide is associated with increased cancer risk (255, 256).  
5.3.2 Paper 2 
5.3.2.1 Renal cell cancer 
The results regarding the association between coffee intake and the risk of renal carcinoma found in 
paper 2 are in agreement with most previously published studies. In a recent meta-analyses of 22 
observational studies, Wijarnpreecha et al. found no association between high coffee consumption and 
the risk of renal cell carcinoma in overall and gender-stratified analyses (257).  
In the prospective study from Norway, Stensvold and Jacobsen found no association between coffee 
consumption and the risk of renal carcinoma (85). The same was found in two cohorts from United 
States - the Nurses’ Health study (258), and the National Cancer Institute - Prostate, 
Lung, Colorectal and Ovarian Cancer Screening Trial (137), as well as in the The Million Women 
study from United Kingdom (259).  
Contrary to these studies, the results from the VIP cohort, which included only 56 cases of renal cell 
carcinoma, have shown that a total coffee consumption of ≥4 cups/day was associated with 70% 
reduced risk of renal cell carcinoma (95% CI 21% - 89%) compared to coffee consumption of <1 
cup/day. The analysis was, however, limited due to a low number of cases in the highest coffee 
consumption category (9 cases) and in the reference category (8 cases). No significant association was 
found for filtered and boiled coffee consumption (139).  
5.3.2.2 Esophageal cancer 
In the meta-analysis published in 2013, Zheng et al. concluded that coffee has a protective effect on 
esophageal cancer (260). The summary odds ratio of 16 observational studies for highest vs lowest/no 
coffee consumption category was 0.88 (95% CI: 0.76-1.01). Jacobsen et al. found no association 
between coffee consumption and the risk of esophageal cancer in a study that included only 22 cases 
(84). The study from Japan reported an inverse association between coffee consumption and the risk 
of oral cavity, pharyngeal, and esophageal cancers combined (157 cases; HR = 0.51; 95% CI 0.33-
0.77) (261). The results from the EPIC cohort have shown no evidence of an association between tea 
and coffee consumption and esophageal cancer risk overall, although there were indications that 
increased coffee consumption was associated with decreased risk of esophageal squamous cell 
carcinoma among men (262). This is in line with the conclusions of Islami et al., who stated that there 
was little evidence of an association between coffee consumption and the risk of esophageal cancer 
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after summarizing the results from 22 observational studies (95). Finally, the Working Group of IARC 
stated that the available evidence suggested that even though the risk of esophageal cancer increased 
with the quantity of mate consumed, the trend was statistically significant only when high temperature 
mate was consumed, independent of the amount (83, 97).  
Our results support the findings of the studies that concluded that coffee consumption does not affect 
the risk of esophageal cancer. The main issue with the analyses of coffee and esophageal cancer in 
paper 2 is that the analyses were statistically underpowered. Although the problem was less 
pronounced in the analysis of the entire sample, the issue became more evident in the gender-specific 
analyses and in the analyses stratified according to smoking status.   
5.3.2.3 Bladder cancer 
We did not observe significant association between coffee consumption and the risk of bladder cancer 
in men. This result contradicts the result from the 2015 meta-analysis (ref) in which positive 
association was reported in men (highest vs lowest coffee consumption category meta-OR=1.31; 95% 
CI 1.08-1.59). In both genders, the corresponding meta-OR was 1.33 (95% CI 1.19-1.48) with a 
moderate level of heterogeneity among 6 cohort and 34 case-control studies. On the other hand, 
positive associations among never smokers (meta-OR of 1.72 (95% CI: 1.25 to 2.35) are in 
agreement with our findings (86). In preceding meta-analysis, Zhou et al. concluded that “although 
data from case–control studies suggested that coffee was a risk factor for bladder cancer, there was no 
conclusive evidence on this association because of inconsistencies between case–control and cohort 
studies” (263).  
The results from prospective cohort studies are partially in disagreement with our findings. The study 
from Netherlands found that the coffee was positively associated with the bladder cancer risk in men, 
and inversely associated in women (264). Kuarashi et al. found no association in both genders 
combined. However, they found that the coffee was significantly increasing the risk of bladder cancer 
in men who were never smokers (≥1 cup/day vs almost none HR = 2.48; 95% CI 0.88–7.05) (30). It 
should be noted that the cut-offs of coffee consumption categories used in this analysis were in 
discrepancy with the cut-offs in paper 2. A strong inverse relationship was observed in both genders, 
and in the analyses stratified according to smoking status in the paper by Sugiyama et al. However, 
none of the estimates were statistically significant, which could be the result of a small number of 
cancer cases in each gender and smoking status subgroups (265), a problem which was less 
pronounced in our analyses. Finally, in the large prospective cohort from the United States, coffee 
consumption was positively associated with bladder cancer risk (≥4 cups/d vs coffee abstainers 
HR=1.18; 95% CI 1.05-1.33). The association was additionally attenuated after adjustment for lifetime 
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smoking patterns (P trend = 0.16). The observed association was confined to men, and no such 
association was found in never smokers (266). 
We did not have additional information on smoking measures such as number of cigarettes smoked 
per day, number of pack-years, and/or duration of smoking in years in the Swedish cohort and 
information on family history of bladder cancer was not available in neither of the two cohorts. 
However, as we did not observe any significant positive association between coffee consumption and 
the risk of bladder cancer in the analysis of the entire cohort, we believe that additional adjustment for 
aforementioned factors would not change our conclusions. Regarding the analysis of boiled coffee 
consumption and the risk of bladder cancer in women, we indeed found an increased risk for moderate 
coffee consumers. However, we believe that if residual confounding by smoking was present in the 
analysis, we would have observed the same positive association, if not stronger, for the heavy coffee 
consumers, when in fact we found a non-significant inverse association in that group. 
Our conclusion further suggest that coffee consumption might affect the risk of bladder cancer in 
never smokers. The effect was also observed in the analyses of different coffee types, which is novel 
finding that requires further research. However, again it should be pointed out that the subgroup 
analyses were to some extent statistically underpowered, which demands caution in interpretation of 
the results.  
Occupational exposure to polycyclic aromatic hydrocarbons was previously found to be associated 
with bladder cancer risk (267-270). Polycyclic aromatic hydrocarbons are also carcinogens formed by 
cigarette smoking and are activated by CYP1A2 and NAT2 liver enzymes, which production is 
stimulated by caffeine (28, 30). As discussed in 5.2.1.5, a shared metabolic pathway by nicotine and 
caffeine suggests that metabolism of caffeine might be faster in active smokers (27, 242). This 
provides a possible biological mechanism behind the potential carcinogenic effect of coffee in never 
smokers.    
5.3.2.4 Pancreatic cancer 
Two meta-analyses that were published during one year (2016) had conflicting results (106, 271). Nie 
et al. found that one additional cup of coffee per day was increasing the risk of pancreatic cancer by 
1%, but found no association when comparing highest vs lowest coffee intake categories (meta-
RR=0.99; 95% CI 0.81-1.21), with a moderate level of heterogeneity between the included studies 
(271). On the other hand, Ran et al. summarized the evidence of 20 cohort studies to find the overall 
RR for highest coffee consumption vs lowest coffee consumption of 0.75 (95% CI 0.63-0.86) and 
moderate level of heterogeneity (106).  
Guertin et al. used data from the NIH-AARP Diet and Health cohort and reported no association 
between total, caffeinated, or decaffeinated coffee consumption and the risk of pancreatic cancer either 
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men or women (272). Similarly, no association was found in two studies from Norway, one from 
Finland, in the study of two prospective cohorts from the United States, and in the EPIC cohort (84, 
85, 273-275). The pooled analysis of 14 cohort studies included in the Pooling Project of Prospective 
Studies of Diet and Cancer has shown no statistically significant associations between pancreatic 
cancer risk and intake of coffee (RR = 1.10; 95% CI, 0.81-1.48 comparing ≥900 to <0 g/d; 237g ≈ 
8oz) (276). 
Nilsson et al. included participants from the VIP cohort and found that the consumption of ≥4 
cups/day of boiled coffee was associated with a 2.51-time (95% CI 1.15-5.50) increased risk of 
pancreatic cancer compared to consumption of >1 cup/day, with only 8 cases in the highest boiled 
coffee consumption group. However, they did not find evidence of an association for total or filtered 
coffee consumption (139). The authors of the study in Japan also concluded that coffee consumption 
has no substantial impact on pancreatic cancer risk.  
The protective effect of filtered coffee on the risk of pancreatic cancer observed in our study was also 
found in never smokers but was not observed in men and women separately. In women, we observed 
borderline non-significant inverse associations in both coffee categories, whereas in men, the 
considerable effect size of 0.57 in the highest coffee consumption category was not statistically 
significant at 5% level. Similarly, the lack of statistical power hampered the analysis, as only 105 
pancreatic cancer cases were available in men, contrary to 374 cases in women.   
The difference in diet between consumers of boiled and filtered coffee types might give some insight 
in why the inverse association between coffee consumption and the risk of pancreatic cancer was 
found only for filtered coffee. Nilsson et al. have shown that boiled coffee consumers are more likely 
to have more traditional food habits, and are less adapted to a modern, more sedentary lifestyle 
compared to filtered coffee consumers (277). Therefore, we have conducted additional analyses in 
which we have additionally adjusted for the total energy intake and for red meat consumption. Our 
conclusions did not change after the additional adjustment in any of the outcomes.  
Two recent meta-analyses have shown that increased coffee consumption has been inversely 
associated with a risk of type 2 diabetes (278, 279), which is an established risk factor for pancreatic 
cancer (280). In addition to anticarcinogenic properties of coffee compounds discussed in 5.2.1.1, 
Gururajanna et al. found that caffeine could induce apoptosis in human pancreatic adenocarcinoma 
cells (281). As the protective effect was found only for higher filtered coffee intake, anticancerogenic 
effect of coffee diterpenes, kahweol and cafestol seems unlikely, as concentration of these compounds 
in filtered coffee is very low (49-51).   
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5.3.2.5  Stomach cancer 
Between 2014 and 2016, seven meta-analyses were conducted in order to summarize evidence on 
coffee consumption and the stomach/gastric cancer risk. Xie et al. pooled results from 12 cohort 
studies and concluded that coffee consumption was not associated with the gastric cancer risk (109). 
Seven months later, Shen et al. published the study in which they found a meta-RR of 1.24 (95% CI 
1.03-1.49) for developing gastric cancer in the highest coffee consumption category, after combining 
the results from 8 studies (282). One month later, Liu et al. summarized 9 cohort studies and found 
that coffee consumption was indeed increasing the risk of gastric cancer but only of cardia sublocation 
(110). The same year in September, Zeng et al. found a RR of stomach cancer of 1.18 (95% CI 0.90-
1.15) for the highest coffee consumption category after pooling the results from 15 cohort studies, and 
a RR of 1.07 (95% CI 0.95-1.21) for every 3-cup/day increase in total coffee consumption (112). 
October 2015: Li et al. published a meta-analysis of 13 cohort studies and concluded that 
coffee consumption was not associated with the risk of gastric cancer, although they found an 
increased risk in studies from the United States (111). Later that year, Deng et al. reported a 
significantly increased risk between gastric cardia cancer and coffee consumption (meta-RR = 1.50; 
95% CI 1.09-2.07) (113). Finally, Xie et al. revisited the subject, and in an updated meta-analysis of 9 
cohort and 13 case-control studies found that among the studies published over the last ten years, high 
coffee consumption was associated with decreased risk of gastric cancer (RR=0.88; 95% CI 0.77-1.00) 
(283).  
Our findings support the conclusion from the EPIC study, in which no significant association was 
found between total coffee consumption and the risk of gastric cancer overall. However, in the same 
study, increment of 100 mL/day was increasing the risk of cardia cancer by 6% (95% CI 3%-11%) 
(284). Similarly, Larsson et al. found that an increase of 1 cup of coffee per day was associated with a 
22% increased risk of stomach cancer (95% CI = 5%-42%) in the study of Swedish women (285). No 
association between coffee consumption and stomach cancer was found in two studies from Norway 
(84, 85). Similarly, Bidel et al. found that even coffee consumption of at least 10 cups of coffee per 
day did not affect the risk of gastric cancer (273). Finally, the results from the Singapore Chinese 
health study have shown that women who were daily coffee drinkers had RR of 0.63 (95% CI 0.46-
0.87) for developing gastric cancer, compared to women who were coffee abstainers (286).  
An increased risk of gastric cancer associated with high coffee consumption in never smokers warrant 
further investigation. Again, statistical power was one of the challenges, as only 98 cases were 
diagnosed among never smokers and could have been included in the analysis. Further, 




The observed differences between the results in paper 1 and the results from previously published 
studies on coffee and cancer could also be the result of different cut-off points of coffee consumption 
categories that were used. Indeed, only the studies from Finland had the highest category cut-off at the 
values that were higher than in paper 1 ( ≥10 cups/day; (230, 273). In rest of the studies, the highest 
coffee consumption category rarely exceeded 4 cups of coffee per day, which was deemed as high 
moderate coffee consumption in paper 1.  
Moreover, differences between reference categories were also frequent. Most of the studies used 
coffee abstainers as their reference group, unlike in both papers 1 and 2 in which the reference were 
the women who reported drinking no more than 1 cup per day. In the NOWAC questionnaire, women 
could choose from the following answers regarding coffee intake: never/seldom, 1-6 cups/week, 1 
cup/day, 2-3 cups/day, 4-5 cups/day, 6-7 cups/day, and ≥8 cups/day, for each brewing type. As none 
of the offered answers included “never” but rather “never” OR “seldom”, there were no guarantees 
that a woman who had answered never/seldom was actually non-drinker of each coffee type. 
Moreover, the number of women who had answered never/seldom at baseline was only 6 315, 
compared to 17 044 women who were defined as “light consumers” in paper 1. Therefore, choosing 
the women who had answered never/seldom as a reference would have substantially limited the size of 
the group. Moreover, seldom drinking or abstaining from coffee is uncommon in Norway. Therefore, 
we believe that those women could differ from the women who reported drinking coffee more 
frequently, making them less appropriate as a reference group. However, using ≤1 cup/day may 
attenuate risk estimates in papers 1 and 2, as drinking 1 cup/day and being a never coffee drinker are 
different levels of exposure. 
Finally, total coffee consumption in paper 1 was calculated as a sum of filtered, boiled, and instant 
coffee. As discussed in 5.1.1.2, we did not have information on consumption of espresso, cappuccino, 
café latte, macchiato, or decaffeinated coffee, and these types of coffee might have been included in 
the previously published studies. Further, if there was a difference in distribution of coffee species (C. 
arabica vs robusta) that were consumed among participants in different cohorts, this could add to the 
explanations of why the estimates were different in some studies, due to a different antioxidant 
capacity between the species.   
5.3.3 Paper 3 
From 2015 up until this day, five meta-analyses were conducted with the aim to summarize available 
evidence on association between coffee consumption and endometrial cancer risk. In the same period 
one new prospective cohort or case-control studies with same aim were published (1). However, the 
recent meta-analyses, other than the meta-analysis by Lafranconi et al. (93), did not perform optimal 
subgroup analyses according to important risk factors such as smoking or BMI. For example, the study 
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by Zhou et al. included only four studies to assess how BMI modified the coffee and endometrial 
cancer association, and did not conduct further analyses for overweight and obese women (92).  
We conducted a dose-response meta-analysis of observational studies on coffee intake and 
endometrial cancer risk, including further detailed subgroup analyses according to established risk 
factors for endometrial cancer. We found that in both cohort and case-control studies, increased coffee 
consumption was associated with a lower risk of endometrial cancer. Dose-response meta-analyses 
revealed a 3% and 12% risk reduction for every additional cup/day increment based on the 
pooled results from cohort and case-control studies, respectively.  
The results from Paper 3 are in agreement with the previous published meta-analyses (92, 93, 131, 
201, 287-289) and the IARC Monograph evaluation (83). Yu et al. pooled the estimates from four 
cohort studies to find a meta-RR of 0.74 (95% CI 0.63-0.84) for the highest coffee intake category 
compared to lowest (201). Bravi et al. combined the results from seven case-control and two cohort 
studies (287). In their analyses they used method that was similar to our alternative approach and 
found an inverse association in coffee drinkers compared to nondrinkers (meta-RR 0.80; 95% CI: 
0.68-0.94) and in heavy coffee drinkers compared to nondrinkers (meta-RR 0.64; 95% CI: 0.48-0.86). 
The dose-response analysis of case-control studies revealed 7% (95% CI: 4%-11%) lower risk of 
endometrial cancer for every additional cup of coffee. However, no significant dose-response was 
found for cohort studies (287). Je and Giovannucci used the results from ten case-control studies and 
six cohort studies and reported meta-RR for the highest vs lowest categories of coffee intake of 0.71 
(95% CI: 0.62–0.81) after they combined the estimates from both study designs. For the case-control 
studies alone meta-OR was 0.69 (95% CI: 0.55–0.87) and meta-RR of 0.70 (95% CI: 0.61–0.80) was 
found for cohort studies. Similar to our results, the authors observed an inverse association across 
geographical regions. Finally, An increment of one cup per day of coffee intake was associated with 
8% reduced risk of endometrial cancer (95% CI: 5%–10%) (288). 
Yang et al. also utilized the results from both prospective and retrospective studies. Total of 7 cohort 
and 6 case-control studies from Europe (including two studies from Norway that were excluded in 
paper 3 (84, 85)) and North America were used to estimate meta-RR per additional coffee cup of 0.96 
(95% CI 0.95-0.98) for cohort studies, and, similarly to our findings, a stronger association for case-
control studies (meta-RR 0.91; 95% CI 0.87-0.95) (131). Zhou et al. conducted comprehensive meta-
analyses of 13 cohort studies (92). The authors also included studies by Jacobsen et al., and Stensvold 
and Jacobsen; they did not include the results from part of the study by Merritt et al. (132), and the 
study by Hashibe et al., which was published later (137). As stated above, Zhou et al. used only four 
studies in the subgroup analyses of overweight/obese women compared to seven cohorts in the present 
review (92), and found that the women in the highest coffee consumption group that had BMI ≥ 25 
had meta-RR of 0.57 (95% CI 0.46–0.71) of developing endometrial cancer compared to their 
 
55 
counterparts that were in the lowest coffee consumption category. Our more comprehensive subgroup 
analyses according to BMI status revealed that the significant effect of coffee consumption in women 
with BMI over 25 was driven by the effect in women with obesity, as no significant association was 
found in overweight women. The results from dose-response analyses using a linear model were 
similar to results from flexible spline models in our analyses (92). Further, Wang et al. found a similar 
protective effect after pooling the results from 12 cohort studies with meta-RR=0.88 (95% CI 0.85-
0.92) for increment of 2 cups of coffee per day (289). Finally, the results from the meta-analysis by 
Lafranconi et al. in which the results from 12 cohort studies were included, were almost identical to 
the meta-RRs of cohort studies and corresponding subgroup analyses in paper 3 (93).  
As previously mentioned, high coffee intake was found to reduce risk of type 2 diabetes (278, 279), 
which is also an independent risk factor for endometrial cancer (290-292). In addition to already 
mentioned benefits of kahweol, Cardenas et al. reported that coffee diterpene has inhibitory effects on 
tumor cell growth and survival of some types of breast cancer cells (293). Both caffeinated and 
decaffeinated coffee was found to decrease serum C-peptide concentrations, with the strongest effect 
observed in obese women (294). Some studies have shown that elevated levels of C-peptide were 
associated with an increased risk of endometrial cancer (295, 296). High coffee intake was also 
positively associated with increased serum levels of adiponectin (297, 298), a protein secreted by 
adipose tissue with antiinflammatory, antiatherogenic, proapoptotic, and antiproliferative properties 
(299). Based on the results from the recent meta-analyses, Li et al. suggested that adiponectin might be 
a promising tool for the prevention of endometrial cancer in postmenopausal women (300). Finally, 
elevated levels of circulating sex-hormone-binding globulin reduce the concentrations of bioavailable 
sex-steroid hormones, which again were positively associated with a risk of endometrial cancer in high 
concentrations (301). Caffeine was suggested to increase levels of circulating sex-hormone-binding 















1. Intake from 4 to 7 cups of coffee per day might reduce overall risk of cancer.  
2. Coffee consumption even in high quantities was not affecting the risk of ovarian and breast 
cancer. Even though there were some indications that moderate-high coffee consumption 
might reduce the risk of colorectal cancer, the absence of dose-response relationship implied 
no association between coffee intake and colorectal cancer risk. 
3. The positive association between heavy coffee consumption (more than 7 cups/day) and the 
risk of lung cancer is most likely confounded by smoking exposure, as no significant 
association was found in never smokers. 
4. The results from the meta-analysis strengthen the evidence of a protective effect of coffee 
consumption on the risk of endometrial cancer and further suggests that increased coffee 
intake might be particularly beneficial for women with obesity.  
5. Increased consumption of filtered coffee was associated with a lower risk of pancreatic cancer. 
6. In both men and women, filtered and total coffee consumption were not associated with the 
risk of bladder, esophageal, kidney, and stomach cancer. Some evidence of a positive 
association between boiled coffee consumption and the risk of bladder cancer was found only 
in women, with, however, no evidence of dose-response relationship between boiled coffee 
intake and bladder cancer risk. 
7. The positive association between boiled coffee consumption and risk of stomach cancer, and 
between filtered, boiled, and total coffee consumption and risk of bladder cancer was found in 
never smokers. These findings should be interpreted with caution, as the analyses were 















7 Further perspectives 
 
1. More prospective studies are needed to clarify the association between coffee and breast and 
colorectal cancer risk. 
2. The future studies that aim to explore the relationship between coffee consumption and the 
risk of lung cancer should have data with extensive information on smoking exposure such as 
smoking duration, number of cigarettes, long-term exposure to cigarette smoke, time since 
quitting, type of tobacco, etc… These studies should involve multiple cohorts that would 
provide sufficient number of lung cancer cases among never smokers in order to provide 
reasonably precise estimates of coffee intake in this sub-population.  
3. Analysis of different coffee types (filtered, boiled, instant) are warranted for the most 
frequently diagnosed cancer sites. 
4. The studies of coffee consumption and endometrial cancer should aim to clarify the effect of 
coffee in different subgroups, mainly in overweight/obese women. 
5. The future studies on rare cancer sites such as esophageal, bladder, and stomach are warranted 
and should aim to pool several cohorts in order to have sufficient statistical power. This also 
holds true if the aim of the studies is to explore the association of coffee consumption on the 
risk of rare cancers within different subgroups. 
6. More studies are needed that would aim to elucidate the biological mechanisms behind a 
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English translation of the questionnaire  
from series 39  
WOMEN AND CANCER Confidential Autumn 2004  
If you agree to take part, tick YES in the box to the right.  
If you do not wish to take part, avoid reminders by ticking NO and return  
the questionnaire in the envelope provided.  
We ask you to fill out the questionnaire as accurately as possible. 
 
The questionnaire is to be read optically. Please use blue or black pen. Use of comma is not allowed, 
round up from 0.5 to 1. Use block letters. 
 
     I agree to 
take part in 
YES  
          the questionnaire 
survey NO  
Best wishes,  
Eiliv Lund  




Do you still have regular periods? 
… Yes 
… Have irregular periods  
… Unknown (Absent because of  illness, etc.)  
… Unknown (Current use of medication containing estrogen)  
… No 
If No; 
Have they stopped of their own accord? .....  
Have both your fallopian tubes been removed?...  
Have you had your womb removed (hysterectomy)?...  
Other? …  
Age when periods stopped?  .....years 
 
Pregnancies, births and breastfeeding 
Have you ever been pregnant? Yes/No 
 If Yes; how many children have you born totally? .....children 
 How old were you at last birth? .....years 
 
Use of contraceptive pill 
Have you ever used the pill or minipill Yes/No 
If Yes; In how many years have you used the pill totally? .....years 
Are you currently on the pill? Yes/No 
 
Use of hormone preparations with estrogen in menopause  
Have you ever used estrogen pills/plasters? Yes/No  
If Yes; how long have you used estrogen pills/plasters in all? .....years  
How old were you when you first used estrogen pills/plasters? .....years  
Are you currently using pills/plasters? Yes/No 
 
If you replied “Yes”, we ask you to elaborate further on this by answering the questions below. For each period 
of continuous use of the same estrogen preparation, we hope you can tell us how old you were when you started, 
how long you used the same hormone preparation, and what it was called. If you stopped using it for a while, or 
switched to other preparations, you should count this as a new period. If you cannot remember the name of the 
hormone preparation, write 'Unsure'. To help you remember the names of estrogen preparations, please use the 
brochure provided, which contains pictures of estrogen preparations that have been sold in Norway. Please also 





      Age at start Used same estrogen pill/plaster continuously from 
1998 
Name of estrogen 
pill/plaster (see 
brouchure) 
 Year Month Nr  
1.     
2.     
3.     
4.     
5.     
 
Estrogen preparations for vaginal use  
Have you ever used estrogen creams/suppositories? Yes/No 
If Yes; Are you currently using creams/suppositories? Yes/No 
 
Intrauterine device  
Have you ever used an intrauterine device (Levonova)? Yes/No 
If Yes; for how long have you used an IUD all together? ….. years  
How old were you the first time you got an IUD inserted? ….. years  
Are you currently using an IUD? Yes/No 
  
Self-perceived health  
Do you rate your own current state of health  as (tick one box only): 
… Very good …Good …Poor … Very poor 
 
Illness  
Do you have or have you had any of the following illnesses? (tick one or more boxes) 
Yes/ No - If Yes, age when first discovered  
Cancer 
High blood pressure  
Heart failure/heart cramps  
Heart attack  
Stroke  
Diabetes  
Depression (seen a doctor)  
Hypothyreosis  
 
For the following conditions, tick which year they emerged, or give the year for the period before 1991.  
before 98  98 99 00 01 02 03 
Muscle pains (myalgia)  
Fibromyalgia/fibrositis  
Chronical fatigue syndrome  




Forearm (wrist)  
Spine (compression)  
Other fractures, describe.........  
 
Other medication 
Do you currently use any of these preparations daily? Yes/No 
Fontex, Fluoxetin 





If Yes; for how long time have you used this preparation continuously? Months….. Years….. 
Have you ever used any of these preparations? Yes/No 
If Yes; For how long time did you use these preparations continuously? Months….. Years….. 
 
Height and weight  
How tall are you? .....cm  
How much do you weigh at the moment? .....kg  
What was your weight at age 18? .....kg 
Body type 1.st degree (tick one box only): 
….Very thin …. Thin ….Normal ….Heavy ….Very heavy 
   
Smoking habits 
During life, have you smoked more than 100 cigarettes totally? Yes/No  
If yes, please fill in how many cigarettes you smoked on average per day the last five years.  
  Number of cigarettes smoked per day  
0 1-4  5-9  10-14  15-19  20-24  25+  
How old were you when you smoked your first cigarette? ….. years 
Do you smoke on a daily basis at the moment? Yes/No 
 If No, how old were you when you quit? ….. years 
Did any of your parents smoke when you were child? Yes/No 
If Yes, how many cigarettes did they smoke in total per day? .... cigarettes  
 
Breast cancer in the family  
Have any of your close relatives had breast cancer:  






Have you ever been to mammography screening of your breasts? Yes/No 
 If Yes; How old were you first time? ….. years 
How many times have you been screened? 
- After invitation from the Mammography Programme ….. times 
- After referral from doctor ….. times 
- Without referral from doctor ….. times 
 
Physical activity  
Please indicate the level of your physical activity on a scale from very low to very high by age 14, 30 and today. 
The scale goes from 1-10. By physical activity we mean both work in and outside the home, as well as 
training/exercise and other physical activity, such as walking, etc. 
 
Age   Very low             Very high  
14 years  1   2   3   4   5   6   7   8   9   10 
30 years  1   2   3   4   5   6   7   8   9   10  
Today   1   2   3   4   5   6   7   8   9   10 
  
How many hours per day do you walk or stroll ourdoors at mean?  
Seldom/     Less than          ½-1 1-2 more than  






How many stairs (whole floors) do you walk per day on average? ………. 
For each of the following activities you partake in, we ask you to estimate how many minutes per day you 
use on these activities on average. 
 
                 Minutes 










How many hours per day on the workplace do you on average use to   Hours 
     Sit…………………………………………………. 
     Stand………………………………………………. 
     Walk………………………………………………. 
     Lift………………………………………………… 
     Heavy lifting/caretaking………………………….. 
 
Diet  
Do any of the following affect your diet? (More than one tick allowed) 
Vegetarian… Do not eat Norwegian diet on daily basis… Have allergy/intolerance… Chronic illness… 
Anorexia… 
Bulimia… Try to lose weight… Low GI food… 
  
We are interested in finding out about your usual eating habits. For each question, tick how often in the 
last twelve months you have eaten the food in question, and how much you usually eat/drink each time.  
 
Drink 
How many glasses of each kind of milk do you usually drink? (Tick one box on each line).  
Never/  1-4  5-6/  1/  2-3/  4+/  
seldom  wk  wk  day  day  day  
Full cream milk (sweet, sour)  
Semi-skimmed milk (sweet, sour)  
Extra skimmed milk 
Skimmed milk (sweet, sour)  
 
How many cups of each kind of coffee/tea do you usually drink? (Tick one box on each line)  
Never/  1-6   1/  2-3/  4-5/ 6-7/ 8+/  
seldom  wk  day  day  day day day  
Boiled coffee (kokekaffe)  
Filter coffee  




Do you use the following in coffee or tea: 
    Coffee  Tea 
Sugar (non-artificial sweetener) Yes/No  Yes/No 
Milk or cream   Yes/No  Yes/No 
 
How many glasses of water do you usually drink? 
Never/  1-6   1/  2-3/  4-5/ 6-7/ 8+/  
seldom  wk  day  day  day day day  
Tap water and bottled water 
 
How many glasses of juice, limonade and soft drinks do you usually drink? (Tick one box on each line)  
Never/  1-4  5-6/  1/  2-3/  4+/  
seldom  wk  wk  day  day  day  
Orange juice  
Lemonade/soft drinks with sugar  
Lemonade/soft drinks with sugar 
Sugarfree lemonade/soft drinks  
 
Yoghurt/cereals 
How often do you eat yoghurt (equivalent to 1 carton)? (Tick one box only)  
.....never/seldom  ....1/wk .....2-3/wk ....4+/wk  
 
How often do you eat cereals, oat flakes or muesli? (Tick one box only)  
.....never/seldom .....1-3/wk .....4-6/wk .....1/day  
 
Bread  
How many slices of bread/rolls and crispbread do you normally eat? (1/2 roll = 1 slice of bread) (Tick one box 
on each line)  
Never/  1-4  5-7/  2-3/  4-5/  6+ 
seldom  wk  wk  day  day  day  
Wholemeal bread  
Kneippbrød (semi white) 
White bread  
Crispbread, etc.  
 
Below are some questions on use of various kinds of sandwich filling/spread. We want to know how many 
slices of bread with these fillings/spreads you usually eat. If you also use these products on other things 
than bread (e.g., on waffles, in breakfast cereals, porridge), please take this into account when answering 
the questions.  
 
How many slices of bread do you eat with? (Tick one box on each line)  
Never/  1-3  4-6/  1/  2-3/  4+/  
seldom  wk  wk  day  day  day  
Jam  
Brown cheese, full cream  
Brown cheese, low-fat  
White cheese, full cream  
White cheese, low-fat  
Meat fillings/spreads, liver paté  
Shrimp salad, Italian salad, etc. 
 
How many slices of bread per week on average in the last twelve months have you eaten with? (Tick one box 
on each line)  
Never/  1/  2-3/  4-6/  7-9/  10+/  
seldom  wk  wk  week  week  week  
Mackerel in tomato sauce, smoked mackerel  
Caviar  
Herring/Anchovies 
Salmon (cured and smoked) 
Other fish fillings/spreads  
 
What kind of fat do you usually spread on your bread? (Tick more than one box if necessary)  
..... I do not use fat on bread  
..... butter  
..... hard margarine (e.g., Per, Melange)  
..... soft margarine (e.g., Soft)  
..... margarine/butter mix (e.g., Bremykt)  
..... Brelett  
..... low-fat margarine (e.g., Soft light, Letta)  
…. Middle fat margarine (Olivero, Omega) 
 
If you use fat on your bread, how thick a layer do you usually spread on it? (Tick one box only)  
.... very thin scraping (3g)  ..... thin layer (5g)  
..... well-covered (8g)   .... thick layer (12g) 
 
Fruits and vegetables  
How often do you eat fruit? (Tick one box per line only)  
Never/  1-3  1/  2-4/  5-6/  1/ 2+/  
seldom  month  wk  wk  wk  day  day 
Apples/pears  
Oranges, etc.  
Bananas  
Other fruit  
 
How often do you eat various kinds of vegetables? (Tick one box per line)  
Never/  1-3  1/  2/  3/ 4-5/ 6-7/  





Mixed salad  
Tomatoes 
Mixed vegetables (frozen) 
Onions  
Other vegetables  
 
For the vegetables you eat, tick how much you eat each time. (Tick one box for each kind)  
- carrots ....1/2 .....1 .....1 1/2 .....2+  
- cabbage .....1/2dl .....1dl .....11/2dl .....2+dl  
- turnip .....1/2dl .....1dl .....11/2dl .....2+dl  
-broccoli/cauliflower .....1-2 rosette(s) .....3-4 rosettes .....5+ rosettes  
- mixed salad .....1dl .....2dl .....3dl .....4+dl  
- tomatoes ….1/4 ….1/2 ….1 ….2+ 
- mixed vegetables .....1/2dl .....1dl .....2dl .....3+dl 
  
How many potatoes do you usually eat (boiled, fried, mashed)? (Tick one box)  
..... I do not/I seldom eat potatoes  
..... 1-4/wk .....5-6/wk ..... 1/day ..... 2/day ..... 3/day .....4+/day  
 
Rice, spaghetti, porridge, soup 
How often do you eat rice and spaghetti/macaroni? (Tick one box on each line)  
Never/  1/ 1/  2/  3+/  
seldom  month  wk  wk  wk   
Rice  
Spaghetti, macaroni, noodles  
 
How often do you eat porridge? (Tick one box only)  
Never/  1/  2-3/  1/  2-6/  1+/  
seldom  month  month wk  wk  day 
Rice porridge 
Other porridge (oatmeal, etc.) 
 
How often do you eat soup? (Tick one box on each line) 
Never/  1/ 1/  2/  3+/  
seldom  month  wk  wk  wk 
As main course 
As appetizer/lunch/evening meal 
 
Fish  
We would like to know how often you eat fish. Please fill in answers to the questions on fish consumption 
as fully as possible. The availability of fish may vary throughout the year. Please indicate in which seasons 
you eat the different kinds of fish.  
Never/  Same amount  Winter  Spring  Summer  Fall  
seldom  all year  
Cod, saithe, halibut, pollack  
Wolffish, flounder, redfish  
Salmon, trout  
Mackerel  
Herring  
Other fish types 
 
In the periods of the year when you eat fish, how often do you usually eat the following? (Tick one box per line)  
Never/  1/ 2-3/  1/  2+/  
seldom  month  month wk  wk   
Boiled cod, saithe, halibut, pollack  
Fried cod, saithe, halibut, pollack  
Wolffish, flounder, redfish  
Salmon, trout  
Mackerel  
Herring  
Other fish types 
 
If you eat fish, how much do you usually eat each time? (1slice/piece = 150g) (Tick one box on each line)  
- boiled fish (slice).....1 .....1.5 .....2 .....3+  
- fried fish (piece).....1 .....1.5 .....2 .....3+  
 
How many times per year do you eat fish feed? (Tick one box only per line)  
0  1-3  4-6  7-9  10+  
Roe  
Fish liver  
 
If you eat fish liver, how many tablespoonfuls do you usually take each time? (Tick one box only)  
.....1 .....2 .....3-4 .....5-6 .....7+  
 
How often do you eat the following kinds of fish dish? (Tick one box only per line)  
Never/  1/ 2-3/  1/  2+/  
seldom  month  month wk  wk   
Fishcakes/pudding/balls  
Fish stew, fish pie  
Fried fish (in batter), fish fingers 
  
How much do you usually eat of the various dishes? (Tick one box only on each line)  
Fishcakes/pudding/balls (pcs.) (2 fish balls = 1 fishcake).....1 .....2 .....3 .....4+  
Fish stew, fish pie (dl).....1-2 .....3-4 .....5+  
Fried fish (in batter), fish fingers (pcs.) .....1-2 .....3-4 .....5-6 .....7+  
 
In addition to information regarding fish consumption, it is important to gather information on the 
accompaniments served with fish. How often do you use the following together with fish? (Tick one box per line 
only)  
Never/  1/ 2-3/  1/  2+/  
seldom  month  month wk  wk  
Melted or solid butter 
Melted or solid margarine  
Clotted cream (35%)  
Reduced-fat cream (20%)  
Sauce containing fat (white/brown)  
Non-fat sauce (white/brown)  
 
For the various kinds of accompaniments you eat with fish, please tick how much you would normally eat.  
Melted or solid butter (tbs) .....1/2 .....1 .....2-3 .....4+  
Melted or solid margarine (tbs) .....1/2 .....1 .....2-3 .....4+  
Clotted cream (tbs) .....1/2 .....1 .....2-3 .....4+  
Reduced-fat cream (tbs)....1/2 .....1 .....2-3 .....4+  
Sauce containing fat (dl)...1/4 ....1/2.....3/4 .....1 .....2+  
Non-fat sauce (dl) ....1/4 .....1/2 ....3/4....1 .....2+  
 
How often do you eat shellfish (e.g., shrimp, crab)? (Tick one box only)  
..... never/seldom ..... 1/mth ..... 2-3/mth .....1+/wk  
 
Meat 
How often do you eat reindeer meat? 
... Never/seldom …1/month …2-3/month… 1 /wk … 2-3/wk … 4+/wk 
 
How often do you usually eat the following meat and poultry dishes? (Tick only one box for each dish)  
Never/  1/  2-3/  1/  2+/   
seldom  month  month wk  wk 
Steak (cow, pork, mutton)  
Chops  
Beef  
Meat balls, patties  
Sausages  
Stews, hash  
Pizza with meat  
Chicken  
Bacon, pork 
Other meat dishes  
 
If you eat the following dishes, how much do you usually eat? (Tick one box per line)  
Steak (slices) .....1 .....2 .....3 .....4 … 5+  
- Chops (pcs.) .....1/2 .....1 .....1.5 .....2+  
- meat balls, - cakes (pcs.) .....1 .....2 ......3 .....4+  
- sausages (pcs.a 150g) ....1/2 .....1 .....1.5 .....2+  
- stew, hash (dl) .....1-2 .....3 .....4 .....5+  
- pizza with meat (pcs a 100g) ....1 .....2 .....3 .....4+ 
  
Which sauces do you use to meat dishes and pasta dishes? 
Never/  1/  2-3/  1/  2-6/  1+/  






How much do you usually eat of these sauces? 
Gravy (dl) …1/4 …1/2 …3/4 …1 …2+ 
Broth …1/4 …1/2 …3/4 …1 …2+ 
Tomato sauce …1/4 …1/2 …3/4 …1 …2+ 
Creamy sauce …1/4 …1/2 …3/4 …1 …2+ 
 
Other types of food  
How many eggs do you usually eat in the course of a week (fried, boiled, scrambled, omelette)?(Tick one box)  
.....0 .....1 .....2 .....3-4 .....5-6 .....7+  
 
 
How often do you eat ice cream (for dessert, ice lollies, etc.)?  
(Tick once to indicate how often you eat ice cream in summer, and once for the rest of the year)  
Never/  1/  2-3/  1/  2-6/  1+/  
seldom  month  month wk  wk  day 
- in summer  
- rest of the year 
 
How much ice cream do you normally eat each time? (Tick one box)  
.....1dl .....2dl .....3dl .....4+dl  
 
How often do you eat sweet buns, cakes, Danish pastry, waffles, etc. (Tick one box)  
Never/  1-3/  1/  2-3/ 4-6/ 1+/  
seldom  month  wk  wk  wk day 











How often do you eat dessert? (Tick one box)  
Never/  1-3/  1/  2-3/ 4-6/ 1+/  
seldom  month  wk  wk  wk day 
Pudding (chocolate, caramel)  
Ricecream ,mousse  
Compote, fruit porridge, canned fruits 
Strawberries (fresh, frozen) 
Other berries (fresh, frozen) 
  
How often do you eat chocolate? (Tick one box)  
Never/  1-3/  1/  2-3/ 4-6/ 1+/  




If you eat chocolate, how much do you usually eat each time?  
Use the size of a Kvikk-Lunsj (Kit-Kat) as a guide, and indicate how much you eat in relation to that) (Tick one box)  
.....1/4 .....1/2 .....3/4 .....1 .....1.5 .....2+  
 
How often do you eat salty snacks? (Tick one box)  
Never/  1-3/  1/  2-3/ 4-6/ 1+/  
seldom  month  wk  wk  wk day 





Cod liver oil and fish oil capsules 
Do you use cod liver oil (liquid)? Yes/No  
If yes, how often do you use it?(Tick one box for each line)  
Never/  1-3/  1/  2-6/ Daily  
seldom  month  wk  wk   
- in the winter  
- the rest of the year  
 
How much cod liver oil do you usually take at one time?  
.....1ts .....1/2ts .....1+ts  
 
Do you use cod liver oil pills/capsules? Yes/No 
If yes, how often do you take cod liver oil pills/capsules? (Tick one box for each line)  
Never/  1-3/  1/  2-6/ Daily  
seldom  month  wk  wk   
- in the winter  
- the rest of the year  
 
Which type of cod liver oil pills/capsules do you usually use, and how many do you use to take each time?  
Name…………….Amount…… 
 
Dietary supplements  
Do you use other dietary supplements? Yes/No  
If yes, how often do you take such supplements?  
Never/  1-3/  1/  2-6/ Daily  






How many times during a moth do you eat warm meals? 
… Breakfast  …Dinner 
… Lunch  … Evening meal 
 
Alcohol  
Are you a teetotaller? Yes/No 
If No, how often and how much have you drunk on average in the last twelve months?  
(Tick one box on each line)  
Never/  1/  2-3/  1/ 2-4/ 5-6/ 1/ 2+/  
seldom  month  month wk  wk wk day day 
Beer (1/2l)  





Are you (tick one box only):  
.....married ....cohabitant ....single…other …divorced …widow  
 
How many persons are there in your household? Number: .....  
 
What is your household's gross annual income?  
.....less than 150 000 kr .....151 000-300 000 kr  
.....301 000-450 000 kr .....451 000-600 000 kr  
.....more than 750 000 kr  
 
What is your work situation? 
… work full time … work part-time …retired … work at home …education …disabled … rehabilitation 
…unemployed 
 
Do you work outdoors in your job? Yes/No 
If Yes; how many hours per week? …Summer …Winter 
 
Sun habits 
Do you get freckles when you sunbathe? Yes/No 
 
To study the effect of sunbathing on risk of melanoma, we ask you to give information about skin colour.  
Tick on the colour that best matches your skin colour (without sunbathing).  
(coloured scale 1-10)  
 
How many times per year have you been sunburnt to the extent that you skin has become irritated and 
blistered, and peeled afterwards? (One tick for each age-group)  
Age   Never  Max 1/  2-3/ 4-5/ 6 or more/  




How many weeks on average per year have you taken sunbathes in southern Europe?  
Age    Never  1 wk  2-3 wk  4-5 wk 7+wk  
40-49 
50+ 
The last 12 months 
 
How often have you been sunbathing in solarium? 
Age    Never  Seldom 1/month  2-3/month    3-4/month    1+/wk  
40-49 
50+ 
The last 12 months 
 
How often do you shower or take a bath?  
1+/  1/  4-6/  2-3/  1/  2-3/  Seldom/  
day  day  wk  wk  wk  month  never  
With soap/shampoo  
Without soap/shampoo  
 
 
When do you use cream with sun screen? (more than one tick possible)  
....At Easter ....in Norway or outside southern Europe? ....sunbathing in southern Europe  
 
Which sun factors do/did you use in these periods?  
    None 1-4 5-9 10-14 15+ 
Easter  
Norway/outside south Europe  
South Europe  
 
How many irregularly shaped moles larger than 5mm do you have in total on both legs (between the toes 
and the groin)? Three examples of moles larger than 5mm are shown below.  
.....0 .....1 .....2-3 .....4-6 .....7-12 .....13-24 .....25+ 
 
How often do you use the following skin care products? (Tick one box) 
Never/  1/  2-3/  1/ 2-4/ 5-6/ 1/ 2+/  






Finally we would ask about your permission to contact you again per post. We will get your address from 
the central person registry. Yes/No 
Are you willing to give a blood sample? Yes/No 
